Expert_review_group	PMID	Citation	Gene	Data_source	Assay_class_summary	Number_var_total	MAVE_DB	PS3_evidence_weighting_Path	BS3_evidence_weighting_ben
ClinGen Familial Hypercholesterolemia Expert Panel	25647241	"Thormaehlen AS, Schuberth C, Won HH, Blattmann P, Joggerst-Thomalla B, Theiss S, Asselta R, Duga S, Merlini PA, Ardissino D, Lander ES, Gabriel S, Rader DJ, Peloso GM, Pepperkok R, Kathiresan S, Runz H. Systematic cell-based phenotyping of missense alleles empowers rare variant association studies: a case for LDLR and myocardial infarction. PLoS Genet. 2015 Feb 3;11(2):e1004855. doi: 10.1371/journal.pgen.1004855. Erratum in: PLoS Genet. 2015 Mar;11(3):e1005060. PMID: 25647241; PMCID: PMC4409815."	LDLR	Figure 3/ PS3/BS3 code text	Ligand uptake assay	79	No	"strong, moderate and supporting"	strong and supporting
ClinGen PTEN Expert Panel	29706350	"Mighell TL, Evans-Dutson S, O'Roak BJ. A Saturation Mutagenesis Approach to Understanding PTEN Lipid Phosphatase Activity and Genotype-Phenotype Relationships. Am J Hum Genet. 2018 May 3;102(5):943-955. doi: 10.1016/j.ajhg.2018.03.018. Epub 2018 Apr 26. PMID: 29706350; PMCID: PMC5986715."	PTEN	PS3/BS3 code text	Massively parallel functional testing in humanized yeast model for lipid phosphatase activity	8012	Yes	moderate and supporting	supporting
ClinGen PTEN Expert Panel	9811831	"Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513-8. doi: 10.1073/pnas.95.23.13513. PMID: 9811831; PMCID: PMC24850."	PTEN	PS3/BS3 code text	Phosphatase assay 	4	No	moderate and supporting	supporting
ClinGen PTEN Expert Panel	9778245	"Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998 Oct 2;95(1):29-39. doi: 10.1016/s0092-8674(00)81780-8. PMID: 9778245."	PTEN	PS3/BS3 code text	Phosphatase assay 	NA	No	moderate and supporting	supporting
ClinGen PTEN Expert Panel	10866302	"Han SY, Kato H, Kato S, Suzuki T, Shibata H, Ishii S, Shiiba K, Matsuno S, Kanamaru R, Ishioka C. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res. 2000 Jun 15;60(12):3147-51. PMID: 10866302."	PTEN	PS3/BS3 code text	Phosphatase assay 	42	No	moderate and supporting	supporting
ClinGen PTEN Expert Panel	21828076	"Rodríguez-Escudero I, Oliver MD, Andrés-Pons A, Molina M, Cid VJ, Pulido R. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. Hum Mol Genet. 2011 Nov 1;20(21):4132-42. doi: 10.1093/hmg/ddr337. Epub 2011 Aug 9. PMID: 21828076."	PTEN	PS3/BS3 code text	Phosphatase assay/Malachite green assay 	19	No	moderate and supporting	supporting
ClinGen PTEN Expert Panel	26504226	"Costa HA, Leitner MG, Sos ML, Mavrantoni A, Rychkova A, Johnson JR, Newton BW, Yee MC, De La Vega FM, Ford JM, Krogan NJ, Shokat KM, Oliver D, Halaszovich CR, Bustamante CD. Discovery and functional characterization of a neomorphic PTEN mutation. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13976-81. doi: 10.1073/pnas.1422504112. Epub 2015 Oct 26. PMID: 26504226; PMCID: PMC4653168."	PTEN	PS3/BS3 code text	Phosphatase assay 	3	No	moderate and supporting	supporting
ClinGen PTEN Expert Panel	29056325	"Malek M, Kielkowska A, Chessa T, Anderson KE, Barneda D, Pir P, Nakanishi H, Eguchi S, Koizumi A, Sasaki J, Juvin V, Kiselev VY, Niewczas I, Gray A, Valayer A, Spensberger D, Imbert M, Felisbino S, Habuchi T, Beinke S, Cosulich S, Le Novère N, Sasaki T, Clark J, Hawkins PT, Stephens LR. PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K. Mol Cell. 2017 Nov 2;68(3):566-580.e10. doi: 10.1016/j.molcel.2017.09.024. Epub 2017 Oct 19. PMID: 29056325; PMCID: PMC5678281."	PTEN	PS3/BS3 code text	Phosphatase assay 	NA	No	moderate and supporting	supporting
ClinGen PTEN Expert Panel	21194675	"Tan MH, Mester J, Peterson C, Yang Y, Chen JL, Rybicki LA, Milas K, Pederson H, Remzi B, Orloff MS, Eng C. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet. 2011 Jan 7;88(1):42-56. doi: 10.1016/j.ajhg.2010.11.013. Epub 2010 Dec 30. PMID: 21194675; PMCID: PMC3014373."	PTEN	PS3/BS3 code text	Western blot	NA	No	moderate and supporting	supporting
ClinGen PTEN Expert Panel	25527629	"Spinelli L, Black FM, Berg JN, Eickholt BJ, Leslie NR. Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes. J Med Genet. 2015 Feb;52(2):128-34. doi: 10.1136/jmedgenet-2014-102803. Epub 2014 Dec 19. PMID: 25527629; PMCID: PMC4316932."	PTEN	PS3/BS3 code text	Western blot	12	No	moderate and supporting	supporting
ClinGen PTEN Expert Panel	19457929	"Lobo GP, Waite KA, Planchon SM, Romigh T, Nassif NT, Eng C. Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function. Hum Mol Genet. 2009 Aug 1;18(15):2851-62. doi: 10.1093/hmg/ddp220. Epub 2009 May 20. PMID: 19457929; PMCID: PMC2706686."	PTEN	PS3/BS3 code text	Subcellular localization assay 	3	No	moderate and supporting	supporting
ClinGen PTEN Expert Panel	22962422	"He X, Saji M, Radhakrishnan D, Romigh T, Ngeow J, Yu Q, Wang Y, Ringel MD, Eng C. PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden syndrome. J Clin Endocrinol Metab. 2012 Nov;97(11):E2179-87. doi: 10.1210/jc.2012-1991. Epub 2012 Sep 7. PMID: 22962422; PMCID: PMC3485596."	PTEN	PS3/BS3 code text	Subcellular localization assay 	22	No	moderate and supporting	supporting
ClinGen PTEN Expert Panel	25875300	"Gil A, Rodríguez-Escudero I, Stumpf M, Molina M, Cid VJ, Pulido R. A functional dissection of PTEN N-terminus: implications in PTEN subcellular targeting and tumor suppressor activity. PLoS One. 2015 Apr 15;10(4):e0119287. doi: 10.1371/journal.pone.0119287. PMID: 25875300; PMCID: PMC4398541."	PTEN	PS3/BS3 code text	Subcellular localization assay 	8	No	moderate and supporting	supporting
ClinGen PTEN Expert Panel	26504226	"Costa HA, Leitner MG, Sos ML, Mavrantoni A, Rychkova A, Johnson JR, Newton BW, Yee MC, De La Vega FM, Ford JM, Krogan NJ, Shokat KM, Oliver D, Halaszovich CR, Bustamante CD. Discovery and functional characterization of a neomorphic PTEN mutation. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13976-81. doi: 10.1073/pnas.1422504112. Epub 2015 Oct 26. PMID: 26504226; PMCID: PMC4653168."	PTEN	PS3/BS3 code text	Wound healing assay	NA	No	moderate and supporting	supporting
ClinGen PTEN Expert Panel	29056325	"Malek M, Kielkowska A, Chessa T, Anderson KE, Barneda D, Pir P, Nakanishi H, Eguchi S, Koizumi A, Sasaki J, Juvin V, Kiselev VY, Niewczas I, Gray A, Valayer A, Spensberger D, Imbert M, Felisbino S, Habuchi T, Beinke S, Cosulich S, Le Novère N, Sasaki T, Clark J, Hawkins PT, Stephens LR. PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K. Mol Cell. 2017 Nov 2;68(3):566-580.e10. doi: 10.1016/j.molcel.2017.09.024. Epub 2017 Oct 19. PMID: 29056325; PMCID: PMC5678281."	PTEN	PS3/BS3 code text	Invadopodia formation assay	2	No	moderate and supporting	supporting
ClinGen TP53 Expert Panel	12826609	"Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9. doi: 10.1073/pnas.1431692100. Epub 2003 Jun 25. PMID: 12826609; PMCID: PMC166245."	TP53	PS3/BS3 code text 	Transactivation assay	2314	No	moderate and supporting	strong and supporting
ClinGen TP53 Expert Panel	30224644	"Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, Howard TP, Takeda DY, Ly SH, Kim E, Gannon HS, Hurhula B, Sharpe T, Goodale A, Fritchman B, Steelman S, Vazquez F, Tsherniak A, Aguirre AJ, Doench JG, Piccioni F, Roberts CWM, Meyerson M, Getz G, Johannessen CM, Root DE, Hahn WC. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018 Oct;50(10):1381-1387. doi: 10.1038/s41588-018-0204-y. Epub 2018 Sep 17. PMID: 30224644; PMCID: PMC6168352."	TP53	PS3/BS3 code text 	"Protein expression, cell viability, and luciferase competition assays"	8258	Yes	moderate	strong and supporting
ClinGen TP53 Expert Panel	29979965	"Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A, Hopf TA, Marks DS, Oren M, Segal E. A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation. Mol Cell. 2018 Jul 5;71(1):178-190.e8. doi: 10.1016/j.molcel.2018.06.012. Erratum in: Mol Cell. 2018 Sep 6;71(5):873. PMID: 29979965."	TP53	PS3/BS3 code text 	Cell proliferation assay - Massively Parallel experimental system to quantify the anti-proliferative functional capacity of TP53 variants 	9833	Yes	moderate and supporting	strong and supporting
ClinGen Coagulation Factor Deficiency Expert Panel	32766856	"Gao W, Xu Y, Liu H, Gao M, Cao Q, Wang Y, Cui L, Huang R, Shen Y, Li S, Yang H, Chen Y, Li C, Yu H, Li W, Shen G. Characterization of missense mutations in the signal peptide and propeptide of FIX in hemophilia B by a cell-based assay. Blood Adv. 2020 Aug 11;4(15):3659-3667. doi: 10.1182/bloodadvances.2020002520. PMID: 32766856; PMCID: PMC7422117."	F9	F9 Functional Assays: List of approved function assays for F9 variants. 	"Cell-based reporter assay that measures secreted conformation-specific reporter levels and secreted total reporter levels, which corresponds to the FIX protein levels in patients"	28	No	supporting	supporting
ClinGen Thrombosis Expert Panel	23809926	"Maruyama K, Morishita E, Karato M, Kadono T, Sekiya A, Goto Y, Sato T, Nomoto H, Omi W, Tsuzura S, Imai H, Asakura H, Ohtake S, Nakao S. Antithrombin deficiency in three Japanese families: one novel and two reported point mutations in the antithrombin gene. Thromb Res. 2013 Aug;132(2):e118-23. doi: 10.1016/j.thromres.2013.06.001. Epub 2013 Jun 25. PMID: 23809926."	SERPINC1	SERPINC1 functional assay list	AT activity measurement by FXa inhibiton activity assay and thrombin inhibition-based activity assay	3	No	supporting	none
ClinGen Thrombosis Expert Panel	27098529	"Navarro-Fernández J, de la Morena-Barrio ME, Padilla J, Miñano A, Bohdan N, Águila S, Martínez-Martínez I, Sevivas TS, de Cos C, Fernández-Mosteirín N, Llamas P, Asenjo S, Medina P, Souto JC, Overvad K, Kristensen SR, Corral J, Vicente V. Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. Thromb Haemost. 2016 Jul 4;116(1):146-54. doi: 10.1160/TH15-11-0871. Epub 2016 Apr 21. PMID: 27098529."	SERPINC1	SERPINC1 functional assay list	AT activity measurement by FXa inhibiton activity assay using chromogenic methods	NA	No	supporting	none
ClinGen Thrombosis Expert Panel	30237862	"Navarro-Fernández J, Eugenia de la Morena-Barrio M, Martínez-Alonso E, Dybedal I, Toderici M, Bohdan N, Miñano A, Heimdal K, Abildgaard U, Martínez-Menárguez JÁ, Corral J, Vicente V. Biochemical and cellular consequences of the antithrombin p.Met1? mutation identified in a severe thrombophilic family. Oncotarget. 2018 Sep 4;9(69):33202-33214. doi: 10.18632/oncotarget.26059. PMID: 30237862; PMCID: PMC6145704."	SERPINC1	SERPINC1 functional assay list	Anti-FXa activity of antithrombin 	NA	No	supporting	none
ClinGen Thrombosis Expert Panel	23809926	"Maruyama K, Morishita E, Karato M, Kadono T, Sekiya A, Goto Y, Sato T, Nomoto H, Omi W, Tsuzura S, Imai H, Asakura H, Ohtake S, Nakao S. Antithrombin deficiency in three Japanese families: one novel and two reported point mutations in the antithrombin gene. Thromb Res. 2013 Aug;132(2):e118-23. doi: 10.1016/j.thromres.2013.06.001. Epub 2013 Jun 25. PMID: 23809926."	SERPINC1	SERPINC1 functional assay list	AT antigen measurement by ELISA	3	No	supporting	none
ClinGen Thrombosis Expert Panel	23117546	"Deng H, Chen J, Xie H, Gu Y, Yuan K, Wang P, Shen W, Liang W, Zhang H, Zhang J, Xie J, Zhang L. Rare double heterozygous mutations in antithrombin underlie hereditary thrombophilia in a Chinese family. J Thromb Thrombolysis. 2013 Oct;36(3):300-6. doi: 10.1007/s11239-012-0822-7. PMID: 23117546."	SERPINC1	SERPINC1 functional assay list	AT antigen measurement by ELISA	2	No	supporting	none
ClinGen Monogenic Diabetes Expert Panel	37101203	"Gersing S, Cagiada M, Gebbia M, Gjesing AP, Coté AG, Seesankar G, Li R, Tabet D, Weile J, Stein A, Gloyn AL, Hansen T, Roth FP, Lindorff-Larsen K, Hartmann-Petersen R. A comprehensive map of human glucokinase variant activity. Genome Biol. 2023 Apr 26;24(1):97. doi: 10.1186/s13059-023-02935-8. PMID: 37101203; PMCID: PMC10131484."	GCK	BS3 code text  	Multiplexed yeast complementation assay to measure both hyper- and hypoactive GCK variation	9003	No	moderate and supporting	supporting
ClinGen Monogenic Diabetes Expert Panel	15677479	"Gloyn AL, Odili S, Zelent D, Buettger C, Castleden HA, Steele AM, Stride A, Shiota C, Magnuson MA, Lorini R, d'Annunzio G, Stanley CA, Kwagh J, van Schaftingen E, Veiga-da-Cunha M, Barbetti F, Dunten P, Han Y, Grimsby J, Taub R, Ellard S, Hattersley AT, Matschinsky FM. Insights into the structure and regulation of glucokinase from a novel mutation (V62M), which causes maturity-onset diabetes of the young. J Biol Chem. 2005 Apr 8;280(14):14105-13. doi: 10.1074/jbc.M413146200. Epub 2005 Jan 25. PMID: 15677479."	GCK	BS3 code text  	Enzymatic activity assay 	40	No	moderate and supporting	supporting
ClinGen Monogenic Diabetes Expert Panel	25015100	"Raimondo A, Chakera AJ, Thomsen SK, Colclough K, Barrett A, De Franco E, Chatelas A, Demirbilek H, Akcay T, Alawneh H; International NDM Consortium; Flanagan SE, Van De Bunt M, Hattersley AT, Gloyn AL, Ellard S; International NDM Consortium. Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability. Hum Mol Genet. 2014 Dec 15;23(24):6432-40. doi: 10.1093/hmg/ddu360. Epub 2014 Jul 11. PMID: 25015100; PMCID: PMC4240195."	GCK	BS3 code text  	Recombinant mutant GCK proteins were analyzed for kinetic and thermostability characteristics and assigned a relative activity index (RAI) or relative stability index (RSI) value	21	No	moderate and supporting	supporting
ClinGen Monogenic Diabetes Expert Panel	22611063	"Beer NL, Osbak KK, van de Bunt M, Tribble ND, Steele AM, Wensley KJ, Edghill EL, Colcough K, Barrett A, Valentínová L, Rundle JK, Raimondo A, Grimsby J, Ellard S, Gloyn AL. Insights into the pathogenicity of rare missense GCK variants from the identification and functional characterization of compound heterozygous and double mutations inherited in cis. Diabetes Care. 2012 Jul;35(7):1482-4. doi: 10.2337/dc11-2420. Epub 2012 May 18. PMID: 22611063; PMCID: PMC3379612."	GCK	BS3 code text  	Enzyme assay	NA	No	moderate and supporting	supporting
ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis Expert Panel	33011440	"Rofes P, Menéndez M, González S, Tornero E, Gómez C, Vargas-Parra G, Montes E, Salinas M, Solanes A, Brunet J, Teulé A, Capellá G, Feliubadaló L, Del Valle J, Pineda M, Lázaro C. Improving Genetic Testing in Hereditary Cancer by RNA Analysis: Tools to Prioritize Splicing Studies and Challenges in Applying American College of Medical Genetics and Genomics Guidelines. J Mol Diagn. 2020 Dec;22(12):1453-1468. doi: 10.1016/j.jmoldx.2020.09.007. Epub 2020 Oct 1. PMID: 33011440."	APC	APC_specifications_supplementary-material_V2	RNA splicing assay	1	No	"strong, moderate and supporting"	strong and supporting
ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis Expert Panel	15459959	"Aretz S, Uhlhaas S, Sun Y, Pagenstecher C, Mangold E, Caspari R, Möslein G, Schulmann K, Propping P, Friedl W. Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene. Hum Mutat. 2004 Nov;24(5):370-80. doi: 10.1002/humu.20087. PMID: 15459959."	APC	APC_specifications_supplementary-material_V2	Splicing evaluation via transcript analysis and agarose gel electrophoresis	6	No	"very strong, strong, moderate and supporting "	strong and supporting
ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel	23867111	"Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijn CN, Prasetyanti P, Pieterse M, Wientjens E, Seibler J, Hogervorst FB, Jonkers J. A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov. 2013 Oct;3(10):1142-55. doi: 10.1158/2159-8290.CD-13-0094. Epub 2013 Jul 18. PMID: 23867111."	BRCA1	Specifications_Table9_V1.1_2023-11-22	Cisplatin sensitivity assay	74	No	strong	strong
ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel	32546644	"Bouwman P, van der Heijden I, van der Gulden H, de Bruijn R, Braspenning ME, Moghadasi S, Wessels LFA; Dutch-Belgian VUS workgroup; Vreeswijk MPG, Jonkers J. Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays. Clin Cancer Res. 2020 Sep 1;26(17):4559-4568. doi: 10.1158/1078-0432.CCR-20-0255. Epub 2020 Jun 16. Erratum in: Clin Cancer Res. 2022 Oct 14;28(20):4588. PMID: 32546644."	BRCA1	Specifications_Table9_V1.1_2023-11-22:	Cisplatin and olaparib sensitivity assays and a direct repeat GFP (DR-GFP) HRR assay	238	No	strong	strong
ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel	30765603	"Fernandes VC, Golubeva VA, Di Pietro G, Shields C, Amankwah K, Nepomuceno TC, de Gregoriis G, Abreu RBV, Harro C, Gomes TT, Silva RF, Suarez-Kurtz G, Couch FJ, Iversen ES, Monteiro ANA, Carvalho MA. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. J Biol Chem. 2019 Apr 12;294(15):5980-5992. doi: 10.1074/jbc.RA118.005274. Epub 2019 Feb 14. PMID: 30765603; PMCID: PMC6463708."	BRCA1	Specifications_Table9_V1.1_2023-11-22	Transcriptional assay based on a fusion of the GAL4 DNA-binding domain to the BRCA1 C terminus (amino acids 1396-1863)	102	No	strong	strong
ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel	30209399	"Findlay GM, Daza RM, Martin B, Zhang MD, Leith AP, Gasperini M, Janizek JD, Huang X, Starita LM, Shendure J. Accurate classification of BRCA1 variants with saturation genome editing. Nature. 2018 Oct;562(7726):217-222. doi: 10.1038/s41586-018-0461-z. Epub 2018 Sep 12. PMID: 30209399; PMCID: PMC6181777."	BRCA1	Specifications_Table9_V1.1_2023-11-22	Luminescence-based survival assay	3893	Yes	strong	strong
ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel	30257991	"Petitalot A, Dardillac E, Jacquet E, Nhiri N, Guirouilh-Barbat J, Julien P, Bouazzaoui I, Bonte D, Feunteun J, Schnell JA, Lafitte P, Aude JC, Noguès C, Rouleau E, Lidereau R, Lopez BS, Zinn-Justin S, Caputo SM; UNICANCER Genetic Group BRCA network. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk. Mol Cancer Res. 2019 Jan;17(1):54-69. doi: 10.1158/1541-7786.MCR-17-0357. Epub 2018 Sep 26. PMID: 30257991."	BRCA1	Specifications_Table9_V1.1_2023-11-22	"Combined workflow including HR assay, localization after DNA damage and in vitro (protein stability upon expression in bacteria and binding to a set of 5 phosphopeptides)"	78	No	strong	strong
ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel	30219179	"Starita LM, Islam MM, Banerjee T, Adamovich AI, Gullingsrud J, Fields S, Shendure J, Parvin JD. A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function. Am J Hum Genet. 2018 Oct 4;103(4):498-508. doi: 10.1016/j.ajhg.2018.07.016. Epub 2018 Sep 12. PMID: 30219179; PMCID: PMC6174279."	BRCA1	Specifications_Table9_V1.1_2023-11-22	Multiplex HDR reporter assay 	1056	Yes	strong	strong
ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel	33293522	"Biswas K, Lipton GB, Stauffer S, Sullivan T, Cleveland L, Southon E, Reid S, Magidson V, Iversen ES Jr, Sharan SK. A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays. NPJ Genom Med. 2020 Dec 8;5(1):52. doi: 10.1038/s41525-020-00158-5. PMID: 33293522; PMCID: PMC7722754."	BRCA2	Specifications_Table9_V1.1_2023-11-22	Mouse embryonic stem cell (mESC)-based assay	88	No	strong	strong
ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel	29884841	"Hart SN, Hoskin T, Shimelis H, Moore RM, Feng B, Thomas A, Lindor NM, Polley EC, Goldgar DE, Iversen E, Monteiro ANA, Suman VJ, Couch FJ. Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. Genet Med. 2019 Jan;21(1):71-80. doi: 10.1038/s41436-018-0018-4. Epub 2018 Jun 8. PMID: 29884841; PMCID: PMC6287763."	BRCA2	Specifications_Table9_V1.1_2023-11-22	Cell-based homology directed DNA repair activity assay	207	No	strong	strong
ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel	32444794	"Ikegami M, Kohsaka S, Ueno T, Momozawa Y, Inoue S, Tamura K, Shimomura A, Hosoya N, Kobayashi H, Tanaka S, Mano H. High-throughput functional evaluation of BRCA2 variants of unknown significance. Nat Commun. 2020 May 22;11(1):2573. doi: 10.1038/s41467-020-16141-8. PMID: 32444794; PMCID: PMC7244490."	BRCA2	Specifications_Table9_V1.1_2023-11-22	"The MANO-B method, for high-throughput functional evaluation utilizing BRCA2-deficient cells and poly (ADP-ribose) polymerase (PARP) inhibitors."	186	No	strong	strong
ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel	29988080	"Mesman RLS, Calléja FMGR, Hendriks G, Morolli B, Misovic B, Devilee P, van Asperen CJ, Vrieling H, Vreeswijk MPG. The functional impact of variants of uncertain significance in BRCA2. Genet Med. 2019 Feb;21(2):293-302. doi: 10.1038/s41436-018-0052-2. Epub 2018 Jul 10. PMID: 29988080; PMCID: PMC6752316."	BRCA2	Specifications_Table9_V1.1_2023-11-22	HDR assays and sensitivity assays with cisplatin and PARP inhibitor treatment	77	No	strong	strong
ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel	33609447	"Richardson ME, Hu C, Lee KY, LaDuca H, Fulk K, Durda KM, Deckman AM, Goldgar DE, Monteiro ANA, Gnanaolivu R, Hart SN, Polley EC, Chao E, Pesaran T, Couch FJ. Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance. Am J Hum Genet. 2021 Mar 4;108(3):458-468. doi: 10.1016/j.ajhg.2021.02.005. Epub 2021 Feb 19. PMID: 33609447; PMCID: PMC8008494."	BRCA2	Specifications_Table9_V1.1_2023-11-22	Homology-directed DNA repair (HDR) assay	252	No	strong	strong
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	9758612	"Arredondo-Vega FX, Santisteban I, Daniels S, Toutain S, Hershfield MS. Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles. Am J Hum Genet. 1998 Oct;63(4):1049-59. doi: 10.1086/302054. PMID: 9758612; PMCID: PMC1377486."	ADA	PS3/BS3 code text in Cspecs	Acitivy/expression assay in ADA-deleted Escherichia coli	29	No	moderate and supporting	supporting
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	25917813	"Felgentreff K, Lee YN, Frugoni F, Du L, van der Burg M, Giliani S, Tezcan I, Reisli I, Mejstrikova E, de Villartay JP, Sleckman BP, Manis J, Notarangelo LD. Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency. J Allergy Clin Immunol. 2015 Jul;136(1):140-150.e7. doi: 10.1016/j.jaci.2015.03.005. Epub 2015 Apr 25. PMID: 25917813; PMCID: PMC4494888."	DCLRE1C	PS3 code in Cspecs	Recombination and DNA repair activity 	41	No	moderate with conditions	none
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	15071507	"Pannicke U, Ma Y, Hopfner KP, Niewolik D, Lieber MR, Schwarz K. Functional and biochemical dissection of the structure-specific nuclease ARTEMIS. EMBO J. 2004 May 5;23(9):1987-97. doi: 10.1038/sj.emboj.7600206. Epub 2004 Apr 8. PMID: 15071507; PMCID: PMC404326."	DCLRE1C	PS3 code in Cspecs	V(D)J recombination assay	19	No	moderate with conditions	none
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	15731174	"Ege M, Ma Y, Manfras B, Kalwak K, Lu H, Lieber MR, Schwarz K, Pannicke U. Omenn syndrome due to ARTEMIS mutations. Blood. 2005 Jun 1;105(11):4179-86. doi: 10.1182/blood-2004-12-4861. Epub 2005 Feb 24. PMID: 15731174."	DCLRE1C	PS3 code in Cspecs	V(D)J recombination assay	3	No	moderate with conditions	none
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	25917813	"Felgentreff K, Lee YN, Frugoni F, Du L, van der Burg M, Giliani S, Tezcan I, Reisli I, Mejstrikova E, de Villartay JP, Sleckman BP, Manis J, Notarangelo LD. Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency. J Allergy Clin Immunol. 2015 Jul;136(1):140-150.e7. doi: 10.1016/j.jaci.2015.03.005. Epub 2015 Apr 25. PMID: 25917813; PMCID: PMC4494888."	DCLRE1C	PS3 code in Cspecs	Recombination and DNA repair activity of human DCLRE1C mutations in Dclre1c(-/-) v-abl kinase-transformed pro-B cells retrovirally engineered for quantititative flow cytometry	41	No	moderate with conditions	none
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	26476407	"Volk T, Pannicke U, Reisli I, Bulashevska A, Ritter J, Björkman A, Schäffer AA, Fliegauf M, Sayar EH, Salzer U, Fisch P, Pfeifer D, Di Virgilio M, Cao H, Yang F, Zimmermann K, Keles S, Caliskaner Z, Güner SÜ, Schindler D, Hammarström L, Rizzi M, Hummel M, Pan-Hammarström Q, Schwarz K, Grimbacher B. DCLRE1C (ARTEMIS) mutations causing phenotypes ranging from atypical severe combined immunodeficiency to mere antibody deficiency. Hum Mol Genet. 2015 Dec 20;24(25):7361-72. doi: 10.1093/hmg/ddv437. Epub 2015 Oct 16. PMID: 26476407; PMCID: PMC4664172."	DCLRE1C	PS3 code in Cspecs 	V(D)J recombination assay	NA	No	moderate with conditions	none
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	11023514	"Roifman CM, Zhang J, Chitayat D, Sharfe N. A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood. 2000 Oct 15;96(8):2803-7. PMID: 11023514."	IL7R	PS3 code in Cspecs 	IL-7-induced Jak3 phosphorylation assay	1	No	supporting	none
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	9843216	"Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998 Dec;20(4):394-7. doi: 10.1038/3877. PMID: 9843216."	IL7R	PS3 code in Cspecs 	IL-7 binding assay	2	No	strong and supporting	none
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	9843216	"Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998 Dec;20(4):394-7. doi: 10.1038/3877. PMID: 9843216."	IL7R	PS3 code in Cspecs 	IL-7-induced STAT5 DNA binding/transcriptional induction	2	No	strong and supporting	none
ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel	16096063	"Jin M, Li S, Moghrabi WN, Sun H, Travis GH. Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. Cell. 2005 Aug 12;122(3):449-59. doi: 10.1016/j.cell.2005.06.042. PMID: 16096063; PMCID: PMC2748856."	RPE65	PS3/BS3 code text in Cspecs	Immunoblot Analysis of gene expression 	NA	No	supporting	supporting
ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel	19431183	"Philp AR, Jin M, Li S, Schindler EI, Iannaccone A, Lam BL, Weleber RG, Fishman GA, Jacobson SG, Mullins RF, Travis GH, Stone EM. Predicting the pathogenicity of RPE65 mutations. Hum Mutat. 2009 Aug;30(8):1183-8. doi: 10.1002/humu.21033. PMID: 19431183; PMCID: PMC2717180."	RPE65	PS3/BS3 code text in Cspecs	In vitro assay of RPE65 Isomerohydrolase Activity	11	No	supporting	supporting
ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel	24849605	"Li S, Izumi T, Hu J, Jin HH, Siddiqui AA, Jacobson SG, Bok D, Jin M. Rescue of enzymatic function for disease-associated RPE65 proteins containing various missense mutations in non-active sites. J Biol Chem. 2014 Jul 4;289(27):18943-56. doi: 10.1074/jbc.M114.552117. Epub 2014 May 21. PMID: 24849605; PMCID: PMC4081934."	RPE65	PS3/BS3 code text in Cspecs	RPE65 isomerase activity	8	No	supporting	supporting
ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel	25752820	"Li S, Hu J, Jin RJ, Aiyar A, Jacobson SG, Bok D, Jin M. Temperature-sensitive retinoid isomerase activity of RPE65 mutants associated with Leber Congenital Amaurosis. J Biochem. 2015 Aug;158(2):115-25. doi: 10.1093/jb/mvv028. Epub 2015 Mar 9. PMID: 25752820; PMCID: PMC4516983."	RPE65	PS3/BS3 code text in Cspecs	Retinoid Isomerase Assay	3	No	supporting	supporting
ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel	16150724	"Redmond TM, Poliakov E, Yu S, Tsai JY, Lu Z, Gentleman S. Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13658-63. doi: 10.1073/pnas.0504167102. Epub 2005 Sep 6. PMID: 16150724; PMCID: PMC1224626."	RPE65	PS3/BS3 code text in CSpecs	Retinoid Isomerase Assay	20	No	supporting	supporting
ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel	18599565	"Lorenz B, Poliakov E, Schambeck M, Friedburg C, Preising MN, Redmond TM. A comprehensive clinical and biochemical functional study of a novel RPE65 hypomorphic mutation. Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5235-42. doi: 10.1167/iovs.07-1671. Epub 2008 Jul 3. PMID: 18599565; PMCID: PMC5015590."	RPE65	PS3/BS3 code text in Cspecs	Isomerase activity of mutant RPE65 was assayed in 293F cells and quantified by HPLC analysis of retinoids	4	No	supporting	supporting
ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel	18722466	"Bereta G, Kiser PD, Golczak M, Sun W, Heon E, Saperstein DA, Palczewski K. Impact of retinal disease-associated RPE65 mutations on retinoid isomerization. Biochemistry. 2008 Sep 16;47(37):9856-65. doi: 10.1021/bi800905v. Epub 2008 Aug 23. PMID: 18722466; PMCID: PMC2610467."	RPE65	PS3/BS3 code text in Cspecs	"mRNA expression, reporter and enzymatic activity, tube formation "	6	No	supporting	supporting
ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel	16754667	"Takahashi Y, Chen Y, Moiseyev G, Ma JX. Two point mutations of RPE65 from patients with retinal dystrophies decrease the stability of RPE65 protein and abolish its isomerohydrolase activity. J Biol Chem. 2006 Aug 4;281(31):21820-21826. doi: 10.1074/jbc.M603725200. Epub 2006 Jun 5. PMID: 16754667."	RPE65	PS3/BS3 code text in Cspecs	Isomerohydrolase activity 	2	No	supporting	supporting
ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel	20043869	"Nikolaeva O, Takahashi Y, Moiseyev G, Ma JX. Negative charge of the glutamic acid 417 residue is crucial for isomerohydrolase activity of RPE65. Biochem Biophys Res Commun. 2010 Jan 22;391(4):1757-61. doi: 10.1016/j.bbrc.2009.12.149. Epub 2009 Dec 30. PMID: 20043869; PMCID: PMC2812700."	RPE65	PS3/BS3 code text in Cspecs	Isomerohydrolase activity	2	No	supporting	supporting
ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel	16828753	"Chen Y, Moiseyev G, Takahashi Y, Ma JX. Impacts of two point mutations of RPE65 from Leber's congenital amaurosis on the stability, subcellular localization and isomerohydrolase activity of RPE65. FEBS Lett. 2006 Jul 24;580(17):4200-4. doi: 10.1016/j.febslet.2006.06.078. Epub 2006 Jul 5. PMID: 16828753."	RPE65	PS3 code text in CSpecs	Isomerohydrolase activity	2	No	supporting	supporting
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	14615376	"Roberts JL, Lengi A, Brown SM, Chen M, Zhou YJ, O'Shea JJ, Buckley RH. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood. 2004 Mar 15;103(6):2009-18. doi: 10.1182/blood-2003-06-2104. Epub 2003 Nov 13. PMID: 14615376."	JAK3	PS3 code text in CSpecs	In vitro kinase assay 	9	No	supporting	none
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	24290284	"Lee YN, Frugoni F, Dobbs K, Walter JE, Giliani S, Gennery AR, Al-Herz W, Haddad E, LeDeist F, Bleesing JH, Henderson LA, Pai SY, Nelson RP, El-Ghoneimy DH, El-Feky RA, Reda SM, Hossny E, Soler-Palacin P, Fuleihan RL, Patel NC, Massaad MJ, Geha RS, Puck JM, Palma P, Cancrini C, Chen K, Vihinen M, Alt FW, Notarangelo LD. A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. J Allergy Clin Immunol. 2014 Apr;133(4):1099-108. doi: 10.1016/j.jaci.2013.10.007. Epub 2013 Nov 28. PMID: 24290284; PMCID: PMC4005599."	RAG1	PS3 code text and SCID VCEP PS3_BS3: Functional Evidence (RAG1)	V(D)J recombination assay	79	No	moderate and supporting	none
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	11313270	"Corneo B, Moshous D, Güngör T, Wulffraat N, Philippet P, Le Deist FL, Fischer A, de Villartay JP. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. 2001 May 1;97(9):2772-6. doi: 10.1182/blood.v97.9.2772. PMID: 11313270."	RAG1	PS3 code text and SCID VCEP PS3_BS3: Functional Evidence (RAG1)	V(D)J recombination assay	11	No	supporting	none
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	29772310	"Tirosh I, Yamazaki Y, Frugoni F, Ververs FA, Allenspach EJ, Zhang Y, Burns S, Al-Herz W, Noroski L, Walter JE, Gennery AR, van der Burg M, Notarangelo LD, Lee YN. Recombination activity of human recombination-activating gene 2 (RAG2) mutations and correlation with clinical phenotype. J Allergy Clin Immunol. 2019 Feb;143(2):726-735. doi: 10.1016/j.jaci.2018.04.027. Epub 2018 Jun 18. PMID: 29772310; PMCID: PMC6295349."	RAG2	PS3 code text and SCID VCEP PS3_BS3: Functional Evidence (RAG2)	V(D)J recombination assay	41	No	moderate and supporting	none
ClinGen Severe Combined Immunodeficiency Disease Expert Panel	20234091	"Couëdel C, Roman C, Jones A, Vezzoni P, Villa A, Cortes P. Analysis of mutations from SCID and Omenn syndrome patients reveals the central role of the Rag2 PHD domain in regulating V(D)J recombination. J Clin Invest. 2010 Apr;120(4):1337-44. doi: 10.1172/JCI41305. Epub 2010 Mar 15. PMID: 20234091; PMCID: PMC2846059."	RAG2	PS3 code text and SCID VCEP PS3_BS3: Functional Evidence (RAG2)	V(D)J recombination assay	6	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	12045205	"Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, Trembath RC, Morrell NW. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet. 2002 Jun 15;11(13):1517-25. doi: 10.1093/hmg/11.13.1517. PMID: 12045205."	BMPR2	BMPR2 functional assay guidelines related to PS3	Luciferase relative light readout assay	NA	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	18321866	"Nasim MT, Ghouri A, Patel B, James V, Rudarakanchana N, Morrell NW, Trembath RC. Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertension. Hum Mol Genet. 2008 Jun 1;17(11):1683-94. doi: 10.1093/hmg/ddn059. Epub 2008 Mar 4. PMID: 18321866."	BMPR2	BMPR2 functional assay guidelines related to PS3	Co-immunoprecipitation assay	11	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	12221115	"Nishihara A, Watabe T, Imamura T, Miyazono K. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell. 2002 Sep;13(9):3055-63. doi: 10.1091/mbc.e02-02-0063. PMID: 12221115; PMCID: PMC124142."	BMPR2	BMPR2 functional assay guidelines related to PS3	"Affinity cross linking, immunoprecipitation, immunoblotting, luciferase activity "	6	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	12045205	"Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, Trembath RC, Morrell NW. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet. 2002 Jun 15;11(13):1517-25. doi: 10.1093/hmg/11.13.1517. PMID: 12045205."	BMPR2	BMPR2 functional assay guidelines related to PS3	Radioligand binding assay	NA	No	strong	none
ClinGen Pulmonary Hypertension Expert Panel	23937428	"Upton PD, Davies RJ, Tajsic T, Morrell NW. Transforming growth factor-β(1) represses bone morphogenetic protein-mediated Smad signaling in pulmonary artery smooth muscle cells via Smad3. Am J Respir Cell Mol Biol. 2013 Dec;49(6):1135-45. doi: 10.1165/rcmb.2012-0470OC. PMID: 23937428; PMCID: PMC3931109."	BMPR2	BMPR2 functional assay guidelines related to PS3	Cell proliferation	NA	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	15845886	"Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, Atkinson C, Chen H, Trembath RC, Morrell NW. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res. 2005 May 27;96(10):1053-63. doi: 10.1161/01.RES.0000166926.54293.68. Epub 2005 Apr 21. PMID: 15845886."	BMPR2	BMPR2 functional assay guidelines related to PS3	Cell proliferation	NA	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	33283886	"Shi W, Wang Q, Wang J, Yan X, Feng W, Zhang Q, Zhai C, Chai L, Li S, Xie X, Li M. Activation of yes-associated protein mediates sphingosine-1-phosphate-induced proliferation and migration of pulmonary artery smooth muscle cells and its potential mechanisms. J Cell Physiol. 2021 Jun;236(6):4694-4708. doi: 10.1002/jcp.30193. Epub 2020 Dec 7. PMID: 33283886."	BMPR2	BMPR2 functional assay guidelines related to PS3	Cell proliferation	NA	No	strong	none
ClinGen Pulmonary Hypertension Expert Panel	25187962	"Wang H, Ji R, Meng J, Cui Q, Zou W, Li L, Wang G, Sun L, Li Z, Huo L, Fan Y, Penny DJ. Functional changes in pulmonary arterial endothelial cells associated with BMPR2 mutations. PLoS One. 2014 Sep 4;9(9):e106703. doi: 10.1371/journal.pone.0106703. PMID: 25187962; PMCID: PMC4154762."	BMPR2	BMPR2 functional assay guidelines related to PS3	Cell proliferation	4	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	20186146	"Yamanaka R, Otsuka F, Nakamura K, Yamashita M, Otani H, Takeda M, Matsumoto Y, Kusano KF, Ito H, Makino H. Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension. Hypertens Res. 2010 May;33(5):435-45. doi: 10.1038/hr.2010.16. Epub 2010 Feb 26. PMID: 20186146."	BMPR2	BMPR2 functional assay guidelines related to PS3	Cell proliferation	NA	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	16497988	"Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudarakanchana N, Southwood M, James V, Trembath RC, Morrell NW. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res. 2006 Mar 31;98(6):818-27. doi: 10.1161/01.RES.0000215809.47923.fd. Epub 2006 Feb 23. PMID: 16497988."	BMPR2	BMPR2 functional assay guidelines related to PS3	Cell proliferation	NA	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	28084316	"Hurst LA, Dunmore BJ, Long L, Crosby A, Al-Lamki R, Deighton J, Southwood M, Yang X, Nikolic MZ, Herrera B, Inman GJ, Bradley JR, Rana AA, Upton PD, Morrell NW. TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling. Nat Commun. 2017 Jan 13;8:14079. doi: 10.1038/ncomms14079. PMID: 28084316; PMCID: PMC5241886."	BMPR2	BMPR2 functional assay guidelines related to PS3	Cell proliferation	4	No	strong	none
ClinGen Pulmonary Hypertension Expert Panel	19366699	"Upton PD, Davies RJ, Trembath RC, Morrell NW. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem. 2009 Jun 5;284(23):15794-804. doi: 10.1074/jbc.M109.002881. Epub 2009 Apr 14. PMID: 19366699; PMCID: PMC2708876."	BMPR2	BMPR2 functional assay guidelines related to PS3	Cell proliferation	NA	No	strong	none
ClinGen Pulmonary Hypertension Expert Panel	31826007	"Hiepen C, Jatzlau J, Hildebrandt S, Kampfrath B, Goktas M, Murgai A, Cuellar Camacho JL, Haag R, Ruppert C, Sengle G, Cavalcanti-Adam EA, Blank KG, Knaus P. BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGFβ responses and altered cell mechanics. PLoS Biol. 2019 Dec 11;17(12):e3000557. doi: 10.1371/journal.pbio.3000557. PMID: 31826007; PMCID: PMC6927666."	BMPR2	BMPR2 functional assay guidelines related to PS3	Western Blot for p-SMAD1/5	2	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	34502015	"Bisserier M, Katz MG, Bueno-Beti C, Brojakowska A, Zhang S, Gubara S, Kohlbrenner E, Fazal S, Fargnoli A, Dorfmuller P, Humbert M, Hata A, Goukassian DA, Sassi Y, Hadri L. Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension. Int J Mol Sci. 2021 Aug 24;22(17):9105. doi: 10.3390/ijms22179105. PMID: 34502015; PMCID: PMC8431626."	BMPR2	BMPR2 functional assay guidelines related to PS3	Western Blot for p-SMAD1-5/9	5	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	21622843	"Jiang Y, Nohe A, Bragdon B, Tian C, Rudarakanchana N, Morrell NW, Petersen NO. Trapping of BMP receptors in distinct membrane domains inhibits their function in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2011 Aug;301(2):L218-27. doi: 10.1152/ajplung.00300.2010. Epub 2011 May 27. PMID: 21622843."	BMPR2	BMPR2 functional assay guidelines related to PS3	Western Blot for p-SMAD1-5/8 and SMAD1/5/8	3	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	20095988	"Hamid R, Hedges LK, Austin E, Phillips JA 3rd, Loyd JE, Cogan JD. Transcripts from a novel BMPR2 termination mutation escape nonsense mediated decay by downstream translation re-initiation: implications for treating pulmonary hypertension. Clin Genet. 2010 Mar;77(3):280-6. doi: 10.1111/j.1399-0004.2009.01311.x. Epub 2010 Jan 20. PMID: 20095988; PMCID: PMC3741656."	BMPR2	BMPR2 functional assay guidelines related to PS3	Western Blot for p-SMAD1/5/8 and SMAD1 (without SMAD5/8)	1	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	23590310	"Drake KM, Dunmore BJ, McNelly LN, Morrell NW, Aldred MA. Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2013 Sep;49(3):403-9. doi: 10.1165/rcmb.2013-0100OC. PMID: 23590310; PMCID: PMC3824059."	BMPR2	BMPR2 functional assay guidelines related to PS3	Western blot for p-SMAD1/5 (not 8) and total SMAD1/5/8	7	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	17600318	"Yang X, Lee PJ, Long L, Trembath RC, Morrell NW. BMP4 induces HO-1 via a Smad-independent, p38MAPK-dependent pathway in pulmonary artery myocytes. Am J Respir Cell Mol Biol. 2007 Nov;37(5):598-605. doi: 10.1165/rcmb.2006-0360OC. Epub 2007 Jun 28. PMID: 17600318."	BMPR2	BMPR2 functional assay guidelines related to PS3	Western blot for p-SMAD1/5 (not 8) 	3	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	15845886	"Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, Atkinson C, Chen H, Trembath RC, Morrell NW. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res. 2005 May 27;96(10):1053-63. doi: 10.1161/01.RES.0000166926.54293.68. Epub 2005 Apr 21. PMID: 15845886."	BMPR2	BMPR2 functional assay guidelines related to PS3	Western blot for p-SMAD1 and total SMAD1	3	No	supporting	none
ClinGen Pulmonary Hypertension Expert Panel	12221115	"Nishihara A, Watabe T, Imamura T, Miyazono K. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell. 2002 Sep;13(9):3055-63. doi: 10.1091/mbc.e02-02-0063. PMID: 12221115; PMCID: PMC124142."	BMPR2	BMPR2 functional assay guidelines related to PS3	Western blot for FLAG-Smad5 and phospho-Smad P-Ser	5	No	moderate	none
ClinGen Pulmonary Hypertension Expert Panel	12045205	"Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, Trembath RC, Morrell NW. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet. 2002 Jun 15;11(13):1517-25. doi: 10.1093/hmg/11.13.1517. PMID: 12045205."	BMPR2	BMPR2 functional assay guidelines related to PS3	In-vitro immunofluoresence imaging of GFP-tagged wild-type and mutant BMPR2 by confocal microscopy.	13	No	strong	none
ClinGen Monogenic Diabetes Expert Panel	32910913	"Althari S, Najmi LA, Bennett AJ, Aukrust I, Rundle JK, Colclough K, Molnes J, Kaci A, Nawaz S, van der Lugt T, Hassanali N, Mahajan A, Molven A, Ellard S, McCarthy MI, Bjørkhaug L, Njølstad PR, Gloyn AL. Unsupervised Clustering of Missense Variants in HNF1A Using Multidimensional Functional Data Aids Clinical Interpretation. Am J Hum Genet. 2020 Oct 1;107(4):670-682. doi: 10.1016/j.ajhg.2020.08.016. Epub 2020 Sep 9. PMID: 32910913; PMCID: PMC7536579."	HNF1A	PS3 code text in Cspecs 	Transactivation assay	73	No	moderate	supporting
ClinGen Monogenic Diabetes Expert Panel	12574234	"Bjørkhaug L, Sagen JV, Thorsby P, Søvik O, Molven A, Njølstad PR. Hepatocyte nuclear factor-1 alpha gene mutations and diabetes in Norway. J Clin Endocrinol Metab. 2003 Feb;88(2):920-31. doi: 10.1210/jc.2002-020945. PMID: 12574234."	HNF1A	PS3 code text in Cspecs 	DNA-binding assays 	18	No	supporting	supporting
ClinGen Monogenic Diabetes Expert Panel	24915262	"SIGMA Type 2 Diabetes Consortium; Estrada K, Aukrust I, Bjørkhaug L, Burtt NP, Mercader JM, García-Ortiz H, Huerta-Chagoya A, Moreno-Macías H, Walford G, Flannick J, Williams AL, Gómez-Vázquez MJ, Fernandez-Lopez JC, Martínez-Hernández A, Jiménez-Morales S, Centeno-Cruz F, Mendoza-Caamal E, Revilla-Monsalve C, Islas-Andrade S, Córdova EJ, Soberón X, González-Villalpando ME, Henderson E, Wilkens LR, Le Marchand L, Arellano-Campos O, Ordóñez-Sánchez ML, Rodríguez-Torres M, Rodríguez-Guillén R, Riba L, Najmi LA, Jacobs SB, Fennell T, Gabriel S, Fontanillas P, Hanis CL, Lehman DM, Jenkinson CP, Abboud HE, Bell GI, Cortes ML, Boehnke M, González-Villalpando C, Orozco L, Haiman CA, Tusié-Luna T, Aguilar-Salinas CA, Altshuler D, Njølstad PR, Florez JC, MacArthur DG. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA. 2014 Jun 11;311(22):2305-14. doi: 10.1001/jama.2014.6511. Erratum in: JAMA. 2014 Nov 12:312(18):1932. Jiménez-Morales, Silvia[Added]. PMID: 24915262; PMCID: PMC4425850."	HNF1A	PS3 code text in Cspecs 	Transactivation activity and Electrophoretic Mobility Shift Assay	5	No	supporting	none
ClinGen Monogenic Diabetes Expert Panel	11162430	"Bjørkhaug L, Ye H, Horikawa Y, Søvik O, Molven A, Njølstad PR. MODY associated with two novel hepatocyte nuclear factor-1alpha loss-of-function mutations (P112L and Q466X). Biochem Biophys Res Commun. 2000 Dec 29;279(3):792-8. doi: 10.1006/bbrc.2000.4024. PMID: 11162430."	HNF1A	PS3 code text in CSpecs	Electrophoretic Mobility Shift Assay for DNA binding	2	No	supporting	supporting
"ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel"	18634022	"Mitui M, Nahas SA, Du LT, Yang Z, Lai CH, Nakamura K, Arroyo S, Scott S, Purayidom A, Concannon P, Lavin M, Gatti RA. Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk. Hum Mutat. 2009 Jan;30(1):12-21. doi: 10.1002/humu.20805. PMID: 18634022; PMCID: PMC2776735."	ATM	ATM supplementary Tables 1 and 2	ATM kinase activity assayed by Western Blotting of ATM substrates	12	No	supporting	supporting
"ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel"	19431188	"Barone G, Groom A, Reiman A, Srinivasan V, Byrd PJ, Taylor AM. Modeling ATM mutant proteins from missense changes confirms retained kinase activity. Hum Mutat. 2009 Aug;30(8):1222-30. doi: 10.1002/humu.21034. PMID: 19431188."	ATM	ATM supplementary Tables 1 and 2	ATM kinase activity assayed by Western Blotting of ATM substrates	20	No	supporting	supporting
"ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel"	11805335	"Scott SP, Bendix R, Chen P, Clark R, Dork T, Lavin MF. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):925-30. doi: 10.1073/pnas.012329699. PMID: 11805335; PMCID: PMC117407."	ATM	ATM supplementary Tables 1 and 2	ATM kinase activity assayed by Western Blotting of ATM substrates	10	No	supporting	supporting
"ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel"	18634022	"Mitui M, Nahas SA, Du LT, Yang Z, Lai CH, Nakamura K, Arroyo S, Scott S, Purayidom A, Concannon P, Lavin M, Gatti RA. Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk. Hum Mutat. 2009 Jan;30(1):12-21. doi: 10.1002/humu.20805. PMID: 18634022; PMCID: PMC2776735."	ATM	ATM supplementary Tables 1 and 2	ATM radiosensitivity 	12	No	moderate with conditions	moderate with conditions
"ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel"	11805335	"Scott SP, Bendix R, Chen P, Clark R, Dork T, Lavin MF. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):925-30. doi: 10.1073/pnas.012329699. PMID: 11805335; PMCID: PMC117407."	ATM	ATM supplementary Tables 1 and 2	Radiosensitivity	10	No	moderate with conditions	moderate with conditions
"ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel"	11805335	"Scott SP, Bendix R, Chen P, Clark R, Dork T, Lavin MF. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):925-30. doi: 10.1073/pnas.012329699. PMID: 11805335; PMCID: PMC117407."	ATM	ATM supplementary Tables 1 and 2	Radiosensitivity	10	No	moderate with conditions	moderate with conditions
ClinGen DICER1 and miRNA-Processing Gene Expert Panel	28862265	"Wu MK, Vujanic GM, Fahiminiya S, Watanabe N, Thorner PS, O'Sullivan MJ, Fabian MR, Foulkes WD. Anaplastic sarcomas of the kidney are characterized by DICER1 mutations. Mod Pathol. 2018 Jan;31(1):169-178. doi: 10.1038/modpathol.2017.100. Epub 2017 Sep 1. PMID: 28862265."	DICER1	BS3 code text in CSpecs	Cleavage assay 	9	No	supporting	supporting
ClinGen Cerebral Creatine Deficiency Syndromes Expert Panel	27233232	"DesRoches CL, Bruun T, Wang P, Marshall CR, Mercimek-Mahmutoglu S. Arginine-Glycine Amidinotransferase Deficiency and Functional Characterization of Missense Variants in GATM. Hum Mutat. 2016 Sep;37(9):926-32. doi: 10.1002/humu.23018. Epub 2016 Jun 27. PMID: 27233232."	GATM	PS3/BS3 code text and Appendix 2_ GATM (AGAT) functional studies_SVI_01122021	In vitro expression of cDNA constructs in HeLa cells followed by assay of AGAT activity 	15	No	supporting	supporting
ClinGen Cerebral Creatine Deficiency Syndromes Expert Panel	24415674	"Mercimek-Mahmutoglu S, Ndika J, Kanhai W, de Villemeur TB, Cheillan D, Christensen E, Dorison N, Hannig V, Hendriks Y, Hofstede FC, Lion-Francois L, Lund AM, Mundy H, Pitelet G, Raspall-Chaure M, Scott-Schwoerer JA, Szakszon K, Valayannopoulos V, Williams M, Salomons GS. Thirteen new patients with guanidinoacetate methyltransferase deficiency and functional characterization of nineteen novel missense variants in the GAMT gene. Hum Mutat. 2014 Apr;35(4):462-9. doi: 10.1002/humu.22511. Epub 2014 Mar 6. PMID: 24415674."	GAMT	GAMT functional studies SVI 01122021	GAMT activity and Western blot	19	No	supporting	supporting
ClinGen Cerebral Creatine Deficiency Syndromes Expert Panel	26003046	"Desroches CL, Patel J, Wang P, Minassian B, Marshall CR, Salomons GS, Mercimek-Mahmutoglu S. Carrier frequency of guanidinoacetate methyltransferase deficiency in the general population by functional characterization of missense variants in the GAMT gene. Mol Genet Genomics. 2015 Dec;290(6):2163-71. doi: 10.1007/s00438-015-1067-x. Epub 2015 May 24. PMID: 26003046."	GAMT	GAMT functional studies SVI 01122021	In vitro expression of cDNA constructs in HeLa cells followed by assay of GAMT activity and Western blot 	14	No	supporting	supporting
ClinGen Cerebral Creatine Deficiency Syndromes Expert Panel	26319512	"Mercimek-Mahmutoglu S, Pop A, Kanhai W, Fernandez Ojeda M, Holwerda U, Smith D, Loeber JG, Schielen PC, Salomons GS. A pilot study to estimate incidence of guanidinoacetate methyltransferase deficiency in newborns by direct sequencing of the GAMT gene. Gene. 2016 Jan 1;575(1):127-31. doi: 10.1016/j.gene.2015.08.045. Epub 2015 Aug 28. PMID: 26319512."	GAMT	GAMT functional studies SVI 01122021	In vitro expression of cDNA constructs in GAMT-deficient cell line followed by assay of GAMT activity and Western blot	NA	No	supporting	supporting
ClinGen Rett and Angelman-like Disorders Expert Panel	22460224	"Sepp M, Pruunsild P, Timmusk T. Pitt-Hopkins syndrome-associated mutations in TCF4 lead to variable impairment of the transcription factor function ranging from hypomorphic to dominant-negative effects. Hum Mol Genet. 2012 Jul 1;21(13):2873-88. doi: 10.1093/hmg/dds112. Epub 2012 Mar 28. PMID: 22460224."	TCF4	TCF4 Functional Assays	Subcellular localization assay	9	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	22777675	"Forrest M, Chapman RM, Doyle AM, Tinsley CL, Waite A, Blake DJ. Functional analysis of TCF4 missense mutations that cause Pitt-Hopkins syndrome. Hum Mutat. 2012 Dec;33(12):1676-86. doi: 10.1002/humu.22160. Epub 2012 Jul 27. PMID: 22777675."	TCF4	TCF4 Functional Assays	Subcellular localization assay	NA	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	22777675	"Forrest M, Chapman RM, Doyle AM, Tinsley CL, Waite A, Blake DJ. Functional analysis of TCF4 missense mutations that cause Pitt-Hopkins syndrome. Hum Mutat. 2012 Dec;33(12):1676-86. doi: 10.1002/humu.22160. Epub 2012 Jul 27. PMID: 22777675."	TCF4	TCF4 Functional Assays	Homogenous time-resolved fluorescence assay for measurement of protein-protein interaction	NA	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	17436255	"Zweier C, Peippo MM, Hoyer J, Sousa S, Bottani A, Clayton-Smith J, Reardon W, Saraiva J, Cabral A, Gohring I, Devriendt K, de Ravel T, Bijlsma EK, Hennekam RC, Orrico A, Cohen M, Dreweke A, Reis A, Nurnberg P, Rauch A. Haploinsufficiency of TCF4 causes syndromal mental retardation with intermittent hyperventilation (Pitt-Hopkins syndrome). Am J Hum Genet. 2007 May;80(5):994-1001. doi: 10.1086/515583. Epub 2007 Mar 23. PMID: 17436255; PMCID: PMC1852727."	TCF4	TCF4 Functional Assays	Luciferase assay for measurement of transcriptional activity	3	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	19235238	"de Pontual L, Mathieu Y, Golzio C, Rio M, Malan V, Boddaert N, Soufflet C, Picard C, Durandy A, Dobbie A, Heron D, Isidor B, Motte J, Newburry-Ecob R, Pasquier L, Tardieu M, Viot G, Jaubert F, Munnich A, Colleaux L, Vekemans M, Etchevers H, Lyonnet S, Amiel J. Mutational, functional, and expression studies of the TCF4 gene in Pitt-Hopkins syndrome. Hum Mutat. 2009 Apr;30(4):669-76. doi: 10.1002/humu.20935. PMID: 19235238."	TCF4	TCF4 Functional Assays	Luciferase assay for measurement of transcriptional activity	13	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	22460224	"Sepp M, Pruunsild P, Timmusk T. Pitt-Hopkins syndrome-associated mutations in TCF4 lead to variable impairment of the transcription factor function ranging from hypomorphic to dominant-negative effects. Hum Mol Genet. 2012 Jul 1;21(13):2873-88. doi: 10.1093/hmg/dds112. Epub 2012 Mar 28. PMID: 22460224."	TCF4	TCF4 Functional Assays	Luciferase assay for measurement of transcriptional activity	7	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	22777675	"Forrest M, Chapman RM, Doyle AM, Tinsley CL, Waite A, Blake DJ. Functional analysis of TCF4 missense mutations that cause Pitt-Hopkins syndrome. Hum Mutat. 2012 Dec;33(12):1676-86. doi: 10.1002/humu.22160. Epub 2012 Jul 27. PMID: 22777675."	TCF4	TCF4 Functional Assays	Luciferase assay for measurement of transcriptional activity	NA	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	22460224	"Sepp M, Pruunsild P, Timmusk T. Pitt-Hopkins syndrome-associated mutations in TCF4 lead to variable impairment of the transcription factor function ranging from hypomorphic to dominant-negative effects. Hum Mol Genet. 2012 Jul 1;21(13):2873-88. doi: 10.1093/hmg/dds112. Epub 2012 Mar 28. PMID: 22460224."	TCF4	TCF4 Functional Assays	Electrophoretic mobility shift assay (EMSA)	9	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	22460224	"Sepp M, Pruunsild P, Timmusk T. Pitt-Hopkins syndrome-associated mutations in TCF4 lead to variable impairment of the transcription factor function ranging from hypomorphic to dominant-negative effects. Hum Mol Genet. 2012 Jul 1;21(13):2873-88. doi: 10.1093/hmg/dds112. Epub 2012 Mar 28. PMID: 22460224."	TCF4	TCF4 Functional Assays	Western blot	9	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	22460224	"Sepp M, Pruunsild P, Timmusk T. Pitt-Hopkins syndrome-associated mutations in TCF4 lead to variable impairment of the transcription factor function ranging from hypomorphic to dominant-negative effects. Hum Mol Genet. 2012 Jul 1;21(13):2873-88. doi: 10.1093/hmg/dds112. Epub 2012 Mar 28. PMID: 22460224."	TCF4	TCF4 Functional Assays	Co-fractionation	9	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	16935860	"Bertani I, Rusconi L, Bolognese F, Forlani G, Conca B, De Monte L, Badaracco G, Landsberger N, Kilstrup-Nielsen C. Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation. J Biol Chem. 2006 Oct 20;281(42):32048-56. doi: 10.1074/jbc.M606325200. Epub 2006 Aug 24. PMID: 16935860."	CDKL5	CDKL5 Functional Assays	In vitro autophosphorylation assays	12	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	16935860	"Bertani I, Rusconi L, Bolognese F, Forlani G, Conca B, De Monte L, Badaracco G, Landsberger N, Kilstrup-Nielsen C. Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation. J Biol Chem. 2006 Oct 20;281(42):32048-56. doi: 10.1074/jbc.M606325200. Epub 2006 Aug 24. PMID: 16935860."	CDKL5	CDKL5 Functional Assays	In vitro phosphorylation - TEY assay	12	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	16935860	"Bertani I, Rusconi L, Bolognese F, Forlani G, Conca B, De Monte L, Badaracco G, Landsberger N, Kilstrup-Nielsen C. Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation. J Biol Chem. 2006 Oct 20;281(42):32048-56. doi: 10.1074/jbc.M606325200. Epub 2006 Aug 24. PMID: 16935860."	CDKL5	CDKL5 Functional Assays	Subcellular localization assay	12	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	27265524	"Christianto A, Katayama S, Kameshita I, Inazu T. A novel CDKL5 mutation in a Japanese patient with atypical Rett syndrome. Clin Chim Acta. 2016 Aug 1;459:132-136. doi: 10.1016/j.cca.2016.06.003. Epub 2016 Jun 2. PMID: 27265524."	CDKL5	CDKL5 Functional Assays	In vitro kinase assay	1	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	21280142	"Le Guen T, Fichou Y, Nectoux J, Bahi-Buisson N, Rivier F, Boddaert N, Diebold B, Héron D, Chelly J, Bienvenu T. A missense mutation within the fork-head domain of the forkhead box G1 Gene (FOXG1) affects its nuclear localization. Hum Mutat. 2011 Feb;32(2):E2026-35. doi: 10.1002/humu.21422. Epub 2010 Dec 7. PMID: 21280142."	FOXG1	FOXG1 Functional Assays	Subcellular localization	2	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	22091895	"De Filippis R, Pancrazi L, Bjørgo K, Rosseto A, Kleefstra T, Grillo E, Panighini A, Cardarelli F, Meloni I, Ariani F, Mencarelli MA, Hayek J, Renieri A, Costa M, Mari F. Expanding the phenotype associated with FOXG1 mutations and in vivo FoxG1 chromatin-binding dynamics. Clin Genet. 2012 Oct;82(4):395-403. doi: 10.1111/j.1399-0004.2011.01810.x. Epub 2011 Dec 13. PMID: 22091895."	FOXG1	FOXG1 Functional Assays	Subcellular localization	NA	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	21280142	"Le Guen T, Fichou Y, Nectoux J, Bahi-Buisson N, Rivier F, Boddaert N, Diebold B, Héron D, Chelly J, Bienvenu T. A missense mutation within the fork-head domain of the forkhead box G1 Gene (FOXG1) affects its nuclear localization. Hum Mutat. 2011 Feb;32(2):E2026-35. doi: 10.1002/humu.21422. Epub 2010 Dec 7. PMID: 21280142."	FOXG1	FOXG1 Functional Assays	CDKN1A expression	1	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	22091895	"De Filippis R, Pancrazi L, Bjørgo K, Rosseto A, Kleefstra T, Grillo E, Panighini A, Cardarelli F, Meloni I, Ariani F, Mencarelli MA, Hayek J, Renieri A, Costa M, Mari F. Expanding the phenotype associated with FOXG1 mutations and in vivo FoxG1 chromatin-binding dynamics. Clin Genet. 2012 Oct;82(4):395-403. doi: 10.1111/j.1399-0004.2011.01810.x. Epub 2011 Dec 13. PMID: 22091895."	FOXG1	FOXG1 Functional Assays	Chromatin localization	NA	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	22091895	"De Filippis R, Pancrazi L, Bjørgo K, Rosseto A, Kleefstra T, Grillo E, Panighini A, Cardarelli F, Meloni I, Ariani F, Mencarelli MA, Hayek J, Renieri A, Costa M, Mari F. Expanding the phenotype associated with FOXG1 mutations and in vivo FoxG1 chromatin-binding dynamics. Clin Genet. 2012 Oct;82(4):395-403. doi: 10.1111/j.1399-0004.2011.01810.x. Epub 2011 Dec 13. PMID: 22091895."	FOXG1	FOXG1 Functional Assays	Stability of chromatin binding	NA	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	27929079	"Sheikh TI, Ausió J, Faghfoury H, Silver J, Lane JB, Eubanks JH, MacLeod P, Percy AK, Vincent JB. From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2. Sci Rep. 2016 Dec 8;6:38590. doi: 10.1038/srep38590. PMID: 27929079; PMCID: PMC5144150."	MECP2	MECP2 Functional Assays	MECP2 chromatin binding assay	10	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	23770565	"Lyst MJ, Ekiert R, Ebert DH, Merusi C, Nowak J, Selfridge J, Guy J, Kastan NR, Robinson ND, de Lima Alves F, Rappsilber J, Greenberg ME, Bird A. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat Neurosci. 2013 Jul;16(7):898-902. doi: 10.1038/nn.3434. Epub 2013 Jun 16. PMID: 23770565; PMCID: PMC3786392."	MECP2	MECP2 Functional Assays	MECP2 chromatin binding assay	4	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	29718204	"Guy J, Alexander-Howden B, FitzPatrick L, DeSousa D, Koerner MV, Selfridge J, Bird A. A mutation-led search for novel functional domains in MeCP2. Hum Mol Genet. 2018 Jul 15;27(14):2531-2545. doi: 10.1093/hmg/ddy159. PMID: 29718204; PMCID: PMC6030874."	MECP2	MECP2 Functional Assays	MECP2 chromatin binding assay	4	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	29718204	"Guy J, Alexander-Howden B, FitzPatrick L, DeSousa D, Koerner MV, Selfridge J, Bird A. A mutation-led search for novel functional domains in MeCP2. Hum Mol Genet. 2018 Jul 15;27(14):2531-2545. doi: 10.1093/hmg/ddy159. PMID: 29718204; PMCID: PMC6030874."	MECP2	MECP2 Functional Assays	MECP2 in vitro binding assay	7	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	23770565	"Lyst MJ, Ekiert R, Ebert DH, Merusi C, Nowak J, Selfridge J, Guy J, Kastan NR, Robinson ND, de Lima Alves F, Rappsilber J, Greenberg ME, Bird A. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat Neurosci. 2013 Jul;16(7):898-902. doi: 10.1038/nn.3434. Epub 2013 Jun 16. PMID: 23770565; PMCID: PMC3786392."	MECP2	MECP2 Functional Assays	MECP2 in vitro binding assay	4	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	23452848	"Baker SA, Chen L, Wilkins AD, Yu P, Lichtarge O, Zoghbi HY. An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders. Cell. 2013 Feb 28;152(5):984-96. doi: 10.1016/j.cell.2013.01.038. PMID: 23452848; PMCID: PMC3641682."	MECP2	MECP2 Functional Assays	In vitro transcription repression assay	2	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	15263005	"Cooper EM, Hudson AW, Amos J, Wagstaff J, Howley PM. Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein. J Biol Chem. 2004 Sep 24;279(39):41208-17. doi: 10.1074/jbc.M401302200. Epub 2004 Jul 19. PMID: 15263005."	UBE3A	UBE3A Functional Assays	E3 ubiquitin ligase activity	9	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	26255772	"Yi JJ, Berrios J, Newbern JM, Snider WD, Philpot BD, Hahn KM, Zylka MJ. An Autism-Linked Mutation Disables Phosphorylation Control of UBE3A. Cell. 2015 Aug 13;162(4):795-807. doi: 10.1016/j.cell.2015.06.045. Epub 2015 Aug 6. PMID: 26255772; PMCID: PMC4537845."	UBE3A	UBE3A Functional Assays	E3 ubiquitin ligase activity	16	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	26255772	"Yi JJ, Berrios J, Newbern JM, Snider WD, Philpot BD, Hahn KM, Zylka MJ. An Autism-Linked Mutation Disables Phosphorylation Control of UBE3A. Cell. 2015 Aug 13;162(4):795-807. doi: 10.1016/j.cell.2015.06.045. Epub 2015 Aug 6. PMID: 26255772; PMCID: PMC4537845."	UBE3A	UBE3A Functional Assays	UBE3A protein expression 	19	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	33607653	"Bossuyt SNV, Punt AM, de Graaf IJ, van den Burg J, Williams MG, Heussler H, Elgersma Y, Distel B. Loss of nuclear UBE3A activity is the predominant cause of Angelman syndrome in individuals carrying UBE3A missense mutations. Hum Mol Genet. 2021 Apr 30;30(6):430-442. doi: 10.1093/hmg/ddab050. PMID: 33607653; PMCID: PMC8101352."	UBE3A	UBE3A Functional Assays	UBE3A nuclear localization	31	No	supporting	none
ClinGen Rett and Angelman-like Disorders Expert Panel	31235931	"Avagliano Trezza R, Sonzogni M, Bossuyt SNV, Zampeta FI, Punt AM, van den Berg M, Rotaru DC, Koene LMC, Munshi ST, Stedehouder J, Kros JM, Williams M, Heussler H, de Vrij FMS, Mientjes EJ, van Woerden GM, Kushner SA, Distel B, Elgersma Y. Loss of nuclear UBE3A causes electrophysiological and behavioral deficits in mice and is associated with Angelman syndrome. Nat Neurosci. 2019 Aug;22(8):1235-1247. doi: 10.1038/s41593-019-0425-0. Epub 2019 Jun 24. PMID: 31235931."	UBE3A	UBE3A Functional Assays	UBE3A subcellular localization	NA	No	strong and supporting	strong
ClinGen Coagulation Factor Deficiency Expert Panel	9864159	"Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood. 1999 Jan 1;93(1):176-83. PMID: 9864159."	F8	F8 Approved Functional Assays	One-stage clotting assay	1	No	strong	strong
ClinGen Coagulation Factor Deficiency Expert Panel	30997536	"Pezeshkpoor B, Gazorpak M, Berkemeier AC, Singer H, Pavlova A, Biswas A, Oldenburg J. In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies. Ann Hematol. 2019 Aug;98(8):1855-1865. doi: 10.1007/s00277-019-03691-1. Epub 2019 Apr 17. PMID: 30997536."	F8	F8 Approved Functional Assays	One-stage clotting assay	23	No	strong	strong
ClinGen Coagulation Factor Deficiency Expert Panel	25708597	"Roualdes O, Nougier C, Fretigny M, Talagrand E, Durand B, Negrier C, Vinciguerra C. Usefulness of an in vitro cellular expression model for haemophilia A carrier diagnosis: illustration with five novel mutations in the F8 gene in women with isolated factor VIII:C deficiency. Haemophilia. 2015 May;21(3):e202-e209. doi: 10.1111/hae.12651. Epub 2015 Feb 24. PMID: 25708597."	F8	F8 Approved Functional Assays	One-stage clotting assay	5	No	strong	strong
ClinGen Coagulation Factor Deficiency Expert Panel	9864159	"Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood. 1999 Jan 1;93(1):176-83. PMID: 9864159."	F8	F8 Approved Functional Assays	Two-stage chromogenic assay (modified two-stage assay using the COAMATIC chromogenic assay according to the manufacturer’s instructions.)	6	No	strong	strong
ClinGen Coagulation Factor Deficiency Expert Panel	30997536	"Pezeshkpoor B, Gazorpak M, Berkemeier AC, Singer H, Pavlova A, Biswas A, Oldenburg J. In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies. Ann Hematol. 2019 Aug;98(8):1855-1865. doi: 10.1007/s00277-019-03691-1. Epub 2019 Apr 17. PMID: 30997536."	F8	F8 Approved Functional Assays	Two-stage chromogenic assay	23	No	strong	strong
ClinGen Coagulation Factor Deficiency Expert Panel	25708597	"Roualdes O, Nougier C, Fretigny M, Talagrand E, Durand B, Negrier C, Vinciguerra C. Usefulness of an in vitro cellular expression model for haemophilia A carrier diagnosis: illustration with five novel mutations in the F8 gene in women with isolated factor VIII:C deficiency. Haemophilia. 2015 May;21(3):e202-e209. doi: 10.1111/hae.12651. Epub 2015 Feb 24. PMID: 25708597."	F8	F8 Approved Functional Assays	ELISA assay 	5	No	supporting	supporting
ClinGen Coagulation Factor Deficiency Expert Panel	26915717	"Jourdy Y, Nougier C, Roualdes O, Fretigny M, Durand B, Negrier C, Vinciguerra C. Characterization of five associations of F8 missense mutations containing FVIII B domain mutations. Haemophilia. 2016 Jul;22(4):583-9. doi: 10.1111/hae.12906. Epub 2016 Feb 25. PMID: 26915717."	F8	F8 Approved Functional Assays	FVIII antigen (FVIII:Ag) quantification via ELISA	5	No	supporting	supporting
ClinGen ACADVL Expert Panel	30194637	"Hesse J, Braun C, Behringer S, Matysiak U, Spiekerkoetter U, Tucci S. The diagnostic challenge in very-long chain acyl-CoA dehydrogenase deficiency (VLCADD). J Inherit Metab Dis. 2018 Nov;41(6):1169-1178. doi: 10.1007/s10545-018-0245-5. Epub 2018 Sep 7. PMID: 30194637."	ACADVL	PS3 code text in CSpecs	Enzyme testing of VLCAD activity	403	No	strong	strong
ClinGen VHL Expert Panel	15611064	"Miller F, Kentsis A, Osman R, Pan ZQ. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex. J Biol Chem. 2005 Mar 4;280(9):7985-96. doi: 10.1074/jbc.M413160200. Epub 2004 Dec 20. PMID: 15611064."	VHL	Functional Assay Documentation - Within Other representative PMIDs with HIF1/2 a degredation assays in template 	HIF1/2 a degradation assay	10	No	supporting	supporting
ClinGen VHL Expert Panel	19030229	"Hacker KE, Lee CM, Rathmell WK. VHL type 2B mutations retain VBC complex form and function. PLoS One. 2008;3(11):e3801. doi: 10.1371/journal.pone.0003801. Epub 2008 Nov 25. PMID: 19030229; PMCID: PMC2583047."	VHL	Functional Assay Documentation - Within Other representative PMIDs with HIF1/2 a degredation assays in template 	HIF1/2 a degradation assay	5	No	supporting	supporting
ClinGen VHL Expert Panel	15574766	"Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res. 2004 Dec 1;64(23):8595-603. doi: 10.1158/0008-5472.CAN-04-1430. PMID: 15574766."	VHL	Functional Assay Documentation - Within Other representative PMIDs with HIF1/2 a degredation assays in template 	HIF1/2 a degradation assay	4	No	supporting	supporting
ClinGen VHL Expert Panel	19602254	"Bangiyeva V, Rosenbloom A, Alexander AE, Isanova B, Popko T, Schoenfeld AR. Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes. BMC Cancer. 2009 Jul 14;9:229. doi: 10.1186/1471-2407-9-229. PMID: 19602254; PMCID: PMC2722669."	VHL	Functional Assay Documentation - Within Other representative PMIDs with HIF1/2 a degredation assays in template 	HIF1/2 a degradation assay	14	No	supporting	supporting
ClinGen VHL Expert Panel	21715564	"Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, Moch H. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. Cancer Res. 2011 Aug 15;71(16):5500-11. doi: 10.1158/0008-5472.CAN-11-0757. Epub 2011 Jun 29. PMID: 21715564."	VHL	Functional Assay Documentation	Protein stability assay	NA	No	supporting	none
ClinGen VHL Expert Panel	11331613	"Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet. 2001 May 1;10(10):1029-38. doi: 10.1093/hmg/10.10.1029. Erratum in: Hum Mol Genet. 2021 May 28;30(9):844-845. PMID: 11331613."	VHL	Functional Assay Documentation	In vitro HIF-alpha binding and ubiquitylation	13	No	supporting	none
ClinGen VHL Expert Panel	11331612	"Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 2001 May 1;10(10):1019-27. doi: 10.1093/hmg/10.10.1019. PMID: 11331612."	VHL	Functional Assay Documentation	Immunoprecipitation and immunoblot analysis assessing VHL complex (VCB/VBC) binding fibronectin. 	5	No	supporting	none
ClinGen VHL Expert Panel	11331612	"Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 2001 May 1;10(10):1019-27. doi: 10.1093/hmg/10.10.1019. PMID: 11331612."	VHL	Functional Assay Documentation	ELISA assay 	5	No	supporting	none
ClinGen VHL Expert Panel	11331612	"Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 2001 May 1;10(10):1019-27. doi: 10.1093/hmg/10.10.1019. PMID: 11331612."	VHL	Functional Assay Documentation	Immunofluorescence to assess Fibronectin deposition in extracellular matrix 	5	No	supporting	none
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	22192717	"Damjanovich K, Langa C, Blanco FJ, McDonald J, Botella LM, Bernabeu C, Wooderchak-Donahue W, Stevenson DA, Bayrak-Toydemir P. 5'UTR mutations of ENG cause hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2011 Dec 22;6:85. doi: 10.1186/1750-1172-6-85. PMID: 22192717; PMCID: PMC3277489."	ENG	HTT_Functional-Assays 	mRNA expression assay 	3	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	21967607	"Kim MJ, Kim ST, Lee HD, Lee KY, Seo J, Lee JB, Lee YJ, Oh SP. Clinical and genetic analyses of three Korean families with hereditary hemorrhagic telangiectasia. BMC Med Genet. 2011 Oct 3;12:130. doi: 10.1186/1471-2350-12-130. PMID: 21967607; PMCID: PMC3202234."	ENG	HTT_Functional-Assays 	mRNA expression assay 	NA	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	16690726	"Prigoda NL, Savas S, Abdalla SA, Piovesan B, Rushlow D, Vandezande K, Zhang E, Ozcelik H, Gallie BL, Letarte M. Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations. J Med Genet. 2006 Sep;43(9):722-8. doi: 10.1136/jmg.2006.042606. Epub 2006 May 11. PMID: 16690726; PMCID: PMC2564570."	ENG	HTT_Functional-Assays 	mRNA expression assay	16	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	9366572	"Pece N, Vera S, Cymerman U, White RI Jr, Wrana JL, Letarte M. Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative. J Clin Invest. 1997 Nov 15;100(10):2568-79. doi: 10.1172/JCI119800. PMID: 9366572; PMCID: PMC508458."	ENG	HTT_Functional-Assays 	mRNA expression assay 	6	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	9245986	"Shovlin CL, Hughes JM, Scott J, Seidman CE, Seidman JG. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet. 1997 Jul;61(1):68-79. doi: 10.1086/513906. PMID: 9245986; PMCID: PMC1715873."	ENG	HTT_Functional-Assays 	mRNA expression assay	10	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	16690726	"Prigoda NL, Savas S, Abdalla SA, Piovesan B, Rushlow D, Vandezande K, Zhang E, Ozcelik H, Gallie BL, Letarte M. Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations. J Med Genet. 2006 Sep;43(9):722-8. doi: 10.1136/jmg.2006.042606. Epub 2006 May 11. PMID: 16690726; PMCID: PMC2564570."	ENG	HTT_Functional-Assays 	Protein expression assay 	41	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	9366572	"Pece N, Vera S, Cymerman U, White RI Jr, Wrana JL, Letarte M. Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative. J Clin Invest. 1997 Nov 15;100(10):2568-79. doi: 10.1172/JCI119800. PMID: 9366572; PMCID: PMC508458."	ENG	HTT_Functional-Assays 	Protein expression assay	NA	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	9366572	"Pece N, Vera S, Cymerman U, White RI Jr, Wrana JL, Letarte M. Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative. J Clin Invest. 1997 Nov 15;100(10):2568-79. doi: 10.1172/JCI119800. PMID: 9366572; PMCID: PMC508458."	ENG	HTT_Functional-Assays 	Protein expression assay 	NA	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	22192717	"Damjanovich K, Langa C, Blanco FJ, McDonald J, Botella LM, Bernabeu C, Wooderchak-Donahue W, Stevenson DA, Bayrak-Toydemir P. 5'UTR mutations of ENG cause hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2011 Dec 22;6:85. doi: 10.1186/1750-1172-6-85. PMID: 22192717; PMCID: PMC3277489."	ENG	HTT_Functional-Assays 	Protein expression assay 	3	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	30763665	"Ruiz-Llorente L, Chiapparino E, Plumitallo S, Danesino C, Bayrak-Toydemir P, Pagella F, Manfredi G, Bernabeu C, Jovine L, Olivieri C. Characterization of a mutation in the zona pellucida module of Endoglin that causes Hereditary Hemorrhagic Telangiectasia. Gene. 2019 May 15;696:33-39. doi: 10.1016/j.gene.2019.02.016. Epub 2019 Feb 11. PMID: 30763665."	ENG	HTT_Functional-Assays 	Protein expression assay 	2	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	30728427	"Ruiz-Llorente L, McDonald J, Wooderchak-Donahue W, Briggs E, Chesnutt M, Bayrak-Toydemir P, Bernabeu C. Characterization of a family mutation in the 5' untranslated region of the endoglin gene causative of hereditary hemorrhagic telangiectasia. J Hum Genet. 2019 Apr;64(4):333-339. doi: 10.1038/s10038-019-0564-x. Epub 2019 Feb 6. PMID: 30728427; PMCID: PMC8075931."	ENG	HTT_Functional-Assays 	Protein expression assay 	3	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	10215596	"Raab U, Velasco B, Lastres P, Letamendía A, Calés C, Langa C, Tapia E, López-Bote JP, Páez E, Bernabéu C. Expression of normal and truncated forms of human endoglin. Biochem J. 1999 May 1;339 ( Pt 3)(Pt 3):579-88. PMID: 10215596; PMCID: PMC1220193."	ENG	HTT_Functional-Assays 	Protein expression assay 	4	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	29305977	"Plumitallo S, Ruiz-Llorente L, Langa C, Morini J, Babini G, Cappelletti D, Scelsi L, Greco A, Danesino C, Bernabeu C, Olivieri C. Functional analysis of a novel ENG variant in a patient with hereditary hemorrhagic telangiectasia (HHT) identifies a new Sp1 binding-site. Gene. 2018 Mar 20;647:85-92. doi: 10.1016/j.gene.2018.01.007. Epub 2018 Jan 4. PMID: 29305977."	ENG	HTT_Functional-Assays 	Protein expression assay 	2	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	10545596	"Pece-Barbara N, Cymerman U, Vera S, Marchuk DA, Letarte M. Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. Hum Mol Genet. 1999 Nov;8(12):2171-81. doi: 10.1093/hmg/8.12.2171. PMID: 10545596."	ENG	HTT_Functional-Assays 	Protein expression assay 	4	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	25312062	"Mallet C, Lamribet K, Giraud S, Dupuis-Girod S, Feige JJ, Bailly S, Tillet E. Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function. Hum Mol Genet. 2015 Feb 15;24(4):1142-54. doi: 10.1093/hmg/ddu531. Epub 2014 Oct 13. PMID: 25312062."	ENG	HTT_Functional-Assays 	Protein expression assay 	31	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	25312062	"Mallet C, Lamribet K, Giraud S, Dupuis-Girod S, Feige JJ, Bailly S, Tillet E. Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function. Hum Mol Genet. 2015 Feb 15;24(4):1142-54. doi: 10.1093/hmg/ddu531. Epub 2014 Oct 13. PMID: 25312062."	ENG	HTT_Functional-Assays 	Intracellular signaling assay 	31	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	15993872	"Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, Pérez-Molino A, Hebbel RP, Nguyen J, Bernabéu C, Botella LM. Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res. 2005 Nov 1;68(2):235-48. doi: 10.1016/j.cardiores.2005.06.009. Epub 2005 Jul 5. PMID: 15993872."	ENG	HTT_Functional-Assays 	Intracellular signaling assay 	NA	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	25312062	"Mallet C, Lamribet K, Giraud S, Dupuis-Girod S, Feige JJ, Bailly S, Tillet E. Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function. Hum Mol Genet. 2015 Feb 15;24(4):1142-54. doi: 10.1093/hmg/ddu531. Epub 2014 Oct 13. PMID: 25312062."	ENG	HTT_Functional-Assays 	Binding assay	31	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	28564608	"Saito T, Bokhove M, Croci R, Zamora-Caballero S, Han L, Letarte M, de Sanctis D, Jovine L. Structural Basis of the Human Endoglin-BMP9 Interaction: Insights into BMP Signaling and HHT1. Cell Rep. 2017 May 30;19(9):1917-1928. doi: 10.1016/j.celrep.2017.05.011. PMID: 28564608; PMCID: PMC5464963."	ENG	HTT_Functional-Assays 	Binding assay 	NA	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	29305977	"Plumitallo S, Ruiz-Llorente L, Langa C, Morini J, Babini G, Cappelletti D, Scelsi L, Greco A, Danesino C, Bernabeu C, Olivieri C. Functional analysis of a novel ENG variant in a patient with hereditary hemorrhagic telangiectasia (HHT) identifies a new Sp1 binding-site. Gene. 2018 Mar 20;647:85-92. doi: 10.1016/j.gene.2018.01.007. Epub 2018 Jan 4. PMID: 29305977."	ENG	HTT_Functional-Assays 	Binding assay 	1	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	22022569	"Ali BR, Ben-Rebeh I, John A, Akawi NA, Milhem RM, Al-Shehhi NA, Al-Ameri MM, Al-Shamisi SA, Al-Gazali L. Endoplasmic reticulum quality control is involved in the mechanism of endoglin-mediated hereditary haemorrhagic telangiectasia. PLoS One. 2011;6(10):e26206. doi: 10.1371/journal.pone.0026206. Epub 2011 Oct 14. PMID: 22022569; PMCID: PMC3194820."	ENG	HTT_Functional-Assays	Subcellular protein localization	22	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	25312062	"Mallet C, Lamribet K, Giraud S, Dupuis-Girod S, Feige JJ, Bailly S, Tillet E. Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function. Hum Mol Genet. 2015 Feb 15;24(4):1142-54. doi: 10.1093/hmg/ddu531. Epub 2014 Oct 13. PMID: 25312062."	ENG	HTT_Functional-Assays	Subcellular protein localization 	31	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	15375013	"Sanz-Rodriguez F, Fernandez-L A, Zarrabeitia R, Perez-Molino A, Ramírez JR, Coto E, Bernabeu C, Botella LM. Mutation analysis in Spanish patients with hereditary hemorrhagic telangiectasia: deficient endoglin up-regulation in activated monocytes. Clin Chem. 2004 Nov;50(11):2003-11. doi: 10.1373/clinchem.2004.035287. Epub 2004 Sep 16. PMID: 15375013."	ENG	HTT_Functional-Assays 	Protein expression assay 	NA	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	16470589	"Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, Perez-Molino A, Morales C, Restrepo CM, Ramirez JR, Coto E, Lenato GM, Bernabeu C, Botella LM. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of Endoglin and ALK1. Hum Mutat. 2006 Mar;27(3):295. doi: 10.1002/humu.9413. PMID: 16470589."	ENG	HTT_Functional-Assays 	Protein expression assay 	6	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	25312062	"Mallet C, Lamribet K, Giraud S, Dupuis-Girod S, Feige JJ, Bailly S, Tillet E. Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function. Hum Mol Genet. 2015 Feb 15;24(4):1142-54. doi: 10.1093/hmg/ddu531. Epub 2014 Oct 13. PMID: 25312062."	ENG	HTT_Functional-Assays	Subcellular protein localization	31	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	31630786	"Snellings DA, Gallione CJ, Clark DS, Vozoris NT, Faughnan ME, Marchuk DA. Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1. Am J Hum Genet. 2019 Nov 7;105(5):894-906. doi: 10.1016/j.ajhg.2019.09.010. Epub 2019 Oct 17. PMID: 31630786; PMCID: PMC6848992."	ENG	HTT_Functional-Assays	Somatic variants - DNA next-generation sequencing	NA	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	10767348	"Abdalla SA, Pece-Barbara N, Vera S, Tapia E, Paez E, Bernabeu C, Letarte M. Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. Hum Mol Genet. 2000 May 1;9(8):1227-37. doi: 10.1093/hmg/9.8.1227. PMID: 10767348."	ACVRL1	HTT_Functional-Assays 	Protein expression assay 	7	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	16470589	"Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, Perez-Molino A, Morales C, Restrepo CM, Ramirez JR, Coto E, Lenato GM, Bernabeu C, Botella LM. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of Endoglin and ALK1. Hum Mutat. 2006 Mar;27(3):295. doi: 10.1002/humu.9413. PMID: 16470589."	ACVRL1	HTT_Functional-Assays 	Intracellular signaling assay 	3	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	23124896	"Hume AN, John A, Akawi NA, Al-Awadhi AM, Al-Suwaidi SS, Al-Gazali L, Ali BR. Retention in the endoplasmic reticulum is the underlying mechanism of some hereditary haemorrhagic telangiectasia type 2 ALK1 missense mutations. Mol Cell Biochem. 2013 Jan;373(1-2):247-57. doi: 10.1007/s11010-012-1496-3. Epub 2012 Nov 4. PMID: 23124896."	ACVRL1	HTT_Functional-Assays	Subcellular protein localization	8	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	15993872	"Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, Pérez-Molino A, Hebbel RP, Nguyen J, Bernabéu C, Botella LM. Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res. 2005 Nov 1;68(2):235-48. doi: 10.1016/j.cardiores.2005.06.009. Epub 2005 Jul 5. PMID: 15993872."	ACVRL1	HTT_Functional-Assays	Morphology assay	5	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	15993872	"Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, Pérez-Molino A, Hebbel RP, Nguyen J, Bernabéu C, Botella LM. Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res. 2005 Nov 1;68(2):235-48. doi: 10.1016/j.cardiores.2005.06.009. Epub 2005 Jul 5. PMID: 15993872."	ACVRL1	HTT_Functional-Assays	Morphology assay 	NA	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	15993872	"Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, Pérez-Molino A, Hebbel RP, Nguyen J, Bernabéu C, Botella LM. Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res. 2005 Nov 1;68(2):235-48. doi: 10.1016/j.cardiores.2005.06.009. Epub 2005 Jul 5. PMID: 15993872."	ACVRL1	HTT_Functional-Assays 	Protein expression assay 	5	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	16470589	"Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, Perez-Molino A, Morales C, Restrepo CM, Ramirez JR, Coto E, Lenato GM, Bernabeu C, Botella LM. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of Endoglin and ALK1. Hum Mutat. 2006 Mar;27(3):295. doi: 10.1002/humu.9413. PMID: 16470589."	ACVRL1	HTT_Functional-Assays 	Protein expression assay 	9	No	supporting	supporting
ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel	31630786	"Snellings DA, Gallione CJ, Clark DS, Vozoris NT, Faughnan ME, Marchuk DA. Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1. Am J Hum Genet. 2019 Nov 7;105(5):894-906. doi: 10.1016/j.ajhg.2019.09.010. Epub 2019 Oct 17. PMID: 31630786; PMCID: PMC6848992."	ACVRL1	HTT_Functional-Assays	Somatic variants - DNA next-generation sequencing	NA	No	supporting	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	ASH Abstract	"Robert R Montgomery,Scot A Fahs,Jeremy G Mattson,Hartmut Weiler,Qizhen Shi; A Murine Model of Type 2N VWD Was Developed By CRISPR/Cas9 Gene Editing and Recapitulates Human Type 2N VWD.Blood2018; 132 (Supplement 1): 221. doi:https://doi.org/10.1182/blood-2018-99-110324"	VWF	VCEP supp_VWD 2N functional assays	Knock In mouse model	NA	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	28581694	"Swystun LL, Georgescu I, Mewburn J, Deforest M, Nesbitt K, Hebert K, Dwyer C, Brown C, Notley C, Lillicrap D. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice. J Thromb Haemost. 2017 Aug;15(8):1607-1619. doi: 10.1111/jth.13749. Epub 2017 Jul 17. PMID: 28581694."	VWF	VCEP supp_VWD 2N functional assays	Hydrodynamic	1	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	9129031	"Gu J, Jorieux S, Lavergne JM, Ruan C, Mazurier C, Meyer D. A patient with type 2N von Willebrand disease is heterozygous for a new mutation: Gly22Glu. Demonstration of a defective expression of the second allele by the use of monoclonal antibodies. Blood. 1997 May 1;89(9):3263-9. PMID: 9129031."	VWF	VCEP supp_VWD 2N functional assays	FVIIII binding	3	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	9845532	"Jorieux S, Gaucher C, Goudemand J, Mazurier C. A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization. Blood. 1998 Dec 15;92(12):4663-70. PMID: 9845532."	VWF	VCEP supp_VWD 2N functional assays	FVIIII binding	1	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	10706867	"Allen S, Abuzenadah AM, Blagg JL, Hinks J, Nesbitt IM, Goodeve AC, Gursel T, Ingerslev J, Peake IR, Daly ME. Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood. 2000 Mar 15;95(6):2000-7. PMID: 10706867."	VWF	VCEP supp_VWD 2N functional assays	FVIIII binding	2	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	15213842	"Schneppenheim R, Lenk H, Obser T, Oldenburg J, Oyen F, Schneppenheim S, Schwaab R, Will K, Budde U. Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization. Thromb Haemost. 2004 Jul;92(1):36-41. doi: 10.1160/TH04-02-0084. PMID: 15213842."	VWF	VCEP supp_VWD 2N functional assays	FVIIII binding	2	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	20586924	"Castaman G, Giacomelli SH, Jacobi P, Obser T, Budde U, Rodeghiero F, Haberichter SL, Schneppenheim R. Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype. J Thromb Haemost. 2010 Sep;8(9):2011-6. doi: 10.1111/j.1538-7836.2010.03971.x. PMID: 20586924."	VWF	VCEP supp_VWD 2N functional assays	FVIIII binding	1	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	23636243	"Skipwith CG, Haberichter SL, Gehrand A, Zheng XL. Compromised shear-dependent cleavage of type 2N von Willebrand factor variants by ADAMTS13 in the presence of factor VIII. Thromb Haemost. 2013 Jul;110(1):202-4. doi: 10.1160/TH13-01-0053. Epub 2013 May 2. PMID: 23636243; PMCID: PMC3813456."	VWF	VCEP supp_VWD 2N functional assays	FVIIII binding	3	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	28581694	"Swystun LL, Georgescu I, Mewburn J, Deforest M, Nesbitt K, Hebert K, Dwyer C, Brown C, Notley C, Lillicrap D. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice. J Thromb Haemost. 2017 Aug;15(8):1607-1619. doi: 10.1111/jth.13749. Epub 2017 Jul 17. PMID: 28581694."	VWF	VCEP supp_VWD 2N functional assays	FVIIII binding	3	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	ASH Abstract		VWF	VCEP supp_VWD 2N functional assays	FVIIII binding	NA	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	10845912	"Ajzenberg N, Ribba AS, Rastegar-Lari G, Meyer D, Baruch D. Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation. Blood. 2000 Jun 15;95(12):3796-803. PMID: 10845912."	VWF	VCEP supp_VWD 2A2B2M functional assays	2M Binding LOF	4	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	26345337	"Ma Z, Su J, Zhang J, Ling J, Yin J, Bai X, Ruan C. The co-influence of VWD type 2B/2M mutations in the A1 domain and platelet GPIbα on the rate of cleavage to VWF by ADAMTS13. Thromb Res. 2015 Nov;136(5):987-95. doi: 10.1016/j.thromres.2015.08.008. Epub 2015 Aug 18. PMID: 26345337."	VWF	VCEP supp_VWD 2A2B2M functional assays	2M Binding LOF	1	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	29341351	"Bowman M, Rimmer E, Houston DS, Israels SJ, James P. Discordant von Willebrand factor (VWF) activity in patients with VWF p.Gly1324Ser confirmed in vitro. Haemophilia. 2018 Mar;24(2):e57-e59. doi: 10.1111/hae.13401. Epub 2018 Jan 17. PMID: 29341351."	VWF	VCEP supp_VWD 2A2B2M functional assays	2M Binding LOF	NA	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	2011604	"Ware J, Dent JA, Azuma H, Sugimoto M, Kyrle PA, Yoshioka A, Ruggeri ZM. Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2946-50. doi: 10.1073/pnas.88.7.2946. PMID: 2011604; PMCID: PMC51357."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	1	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	1557393	"Cooney KA, Lyons SE, Ginsburg D. Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2869-72. doi: 10.1073/pnas.89.7.2869. PMID: 1557393; PMCID: PMC48764."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	1	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	1373334	"Kroner PA, Kluessendorf ML, Scott JP, Montgomery RR. Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets. Blood. 1992 Apr 15;79(8):2048-55. PMID: 1373334."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	2	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	1400429	"Randi AM, Jorieux S, Tuley EA, Mazurier C, Sadler JE. Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin. J Biol Chem. 1992 Oct 15;267(29):21187-92. PMID: 1400429."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	4	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	8165601	"Inbal A, Kornbrot N, Harrison P, Randi AM, Sadler JE. Effect of type IIB von Willebrand disease mutation Arg(545)Cys on platelet glycoprotein Ib binding--studies with recombinant von Willebrand factor. Thromb Haemost. 1993 Dec 20;70(6):1058-62. PMID: 8165601."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	1	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	8376405	"Rabinowitz I, Randi AM, Shindler KS, Tuley EA, Rustagi PK, Sadler JE. Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem. 1993 Sep 25;268(27):20497-501. PMID: 8376405."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	1	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	1429668	"Ribba AS, Voorberg J, Meyer D, Pannekoek H, Pietu G. Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease. J Biol Chem. 1992 Nov 15;267(32):23209-15. PMID: 1429668."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	1	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	8298143	"Ribba AS, Christophe O, Derlon A, Cherel G, Siguret V, Lavergne JM, Girma JP, Meyer D, Pietu G. Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease. Blood. 1994 Feb 1;83(3):833-41. PMID: 8298143."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	1	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	8204881	"Christophe O, Ribba AS, Baruch D, Obert B, Rouault C, Niinomi K, Piétu G, Meyer D, Girma JP. Influence of mutations and size of multimers in type II von Willebrand disease upon the function of von Willebrand factor. Blood. 1994 Jun 15;83(12):3553-61. PMID: 8204881."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	3	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	8123843	"Hilbert L, Gaucher C, de Romeuf C, Horellou MH, Vink T, Mazurier C. Leu 697-->Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood. 1994 Mar 15;83(6):1542-50. PMID: 8123843."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	1	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	9858249	"Hilbert L, Gaucher C, Abgrall JF, Parquet A, Trzeciak C, Mazurier C. Identification of new type 2B von Willebrand disease mutations: Arg543Gln, Arg545Pro and Arg578Leu. Br J Haematol. 1998 Dec;103(3):877-84. doi: 10.1046/j.1365-2141.1998.01040.x. PMID: 9858249."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	6	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	8547152	"Hilbert L, Gaucher C, Mazurier C. Effects of different amino-acid substitutions in the leucine 694-proline 708 segment of recombinant von Willebrand factor. Br J Haematol. 1995 Dec;91(4):983-90. doi: 10.1111/j.1365-2141.1995.tb05423.x. PMID: 8547152."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	4	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	8630394	"Cooney KA, Ginsburg D. Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets. Blood. 1996 Mar 15;87(6):2322-8. PMID: 8630394."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	6	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	10845912	"Ajzenberg N, Ribba AS, Rastegar-Lari G, Meyer D, Baruch D. Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation. Blood. 2000 Jun 15;95(12):3796-803. PMID: 10845912."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	5	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	16246252	"Baronciani L, Federici AB, Beretta M, Cozzi G, Canciani MT, Mannucci PM. Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost. 2005 Dec;3(12):2689-94. doi: 10.1111/j.1538-7836.2005.01638.x. Epub 2005 Oct 25. PMID: 16246252."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	2	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	17155947	"Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PM. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease. J Thromb Haemost. 2007 Feb;5(2):282-8. doi: 10.1111/j.1538-7836.2007.02349.x. Epub 2006 Dec 7. PMID: 17155947."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	2	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	26345337	"Ma Z, Su J, Zhang J, Ling J, Yin J, Bai X, Ruan C. The co-influence of VWD type 2B/2M mutations in the A1 domain and platelet GPIbα on the rate of cleavage to VWF by ADAMTS13. Thromb Res. 2015 Nov;136(5):987-95. doi: 10.1016/j.thromres.2015.08.008. Epub 2015 Aug 18. PMID: 26345337."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	3	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	30488424	"Ahmad F, Kannan M, Obser T, Budde U, Schneppenheim S, Saxena R, Schneppenheim R. Characterization of VWF gene conversions causing von Willebrand disease. Br J Haematol. 2019 Mar;184(5):817-825. doi: 10.1111/bjh.15709. Epub 2018 Nov 29. PMID: 30488424."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	6	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	23179108	"Ahmad F, Jan R, Kannan M, Obser T, Hassan MI, Oyen F, Budde U, Saxena R, Schneppenheim R. Characterisation of mutations and molecular studies of type 2 von Willebrand disease. Thromb Haemost. 2013 Jan;109(1):39-46. doi: 10.1160/TH12-07-0475. Epub 2012 Nov 22. PMID: 23179108."	VWF	VCEP supp_VWD 2A2B2M functional assays	2B Binding GOF	5	No	strong	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	16322474	"Hassenpflug WA, Budde U, Obser T, Angerhaus D, Drewke E, Schneppenheim S, Schneppenheim R. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood. 2006 Mar 15;107(6):2339-45. doi: 10.1182/blood-2005-04-1758. Epub 2005 Dec 1. PMID: 16322474."	VWF	VCEP supp_VWD 2A2B2M functional assays	2A ADAMTS13 susceptibility	13	No	supporting	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	22781599	"Zhang JY, Su J, Ma ZN, Dong NZ, Wang YC, Ruan CG. [Increased susceptibility of recombinant type 2A von Willebrand factor mutant A1500E to proteolysis by ADAMTS13]. Zhonghua Xue Ye Xue Za Zhi. 2012 Mar;33(3):169-72. Chinese. PMID: 22781599."	VWF	VCEP supp_VWD 2A2B2M functional assays	2A ADAMTS13 susceptibility	1	No	supporting	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	22431572	"Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood. 2012 May 10;119(19):4543-53. doi: 10.1182/blood-2011-06-360875. Epub 2012 Mar 19. PMID: 22431572; PMCID: PMC3362367."	VWF	VCEP supp_VWD 2A2B2M functional assays	2A ADAMTS13 susceptibility	6	No	supporting	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	23110044	"Interlandi G, Ling M, Tu AY, Chung DW, Thomas WE. Structural basis of type 2A von Willebrand disease investigated by molecular dynamics simulations and experiments. PLoS One. 2012;7(10):e45207. doi: 10.1371/journal.pone.0045207. Epub 2012 Oct 23. PMID: 23110044; PMCID: PMC3479114."	VWF	VCEP supp_VWD 2A2B2M functional assays	2A ADAMTS13 susceptibility	6	No	supporting	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	28076816	"Aponte-Santamaría C, Lippok S, Mittag JJ, Obser T, Schneppenheim R, Baldauf C, Gräter F, Budde U, Rädler JO. Mutation G1629E Increases von Willebrand Factor Cleavage via a Cooperative Destabilization Mechanism. Biophys J. 2017 Jan 10;112(1):57-65. doi: 10.1016/j.bpj.2016.11.3202. PMID: 28076816; PMCID: PMC5232862."	VWF	VCEP supp_VWD 2A2B2M functional assays	2A ADAMTS13 susceptibility	1	No	supporting	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	29186156	"Lynch CJ, Cawte AD, Millar CM, Rueda D, Lane DA. A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET construct. PLoS One. 2017 Nov 29;12(11):e0188405. doi: 10.1371/journal.pone.0188405. PMID: 29186156; PMCID: PMC5706690."	VWF	VCEP supp_VWD 2A2B2M functional assays	2A ADAMTS13 susceptibility	11	No	supporting	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	11264172	"Schneppenheim R, Budde U, Obser T, Brassard J, Mainusch K, Ruggeri ZM, Schneppenheim S, Schwaab R, Oldenburg J. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. Blood. 2001 Apr 1;97(7):2059-66. doi: 10.1182/blood.v97.7.2059. PMID: 11264172."	VWF	VCEP supp_VWD 2A2B2M functional assays	2A multimerization	2	No	strong and supporting	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	16322474	"Hassenpflug WA, Budde U, Obser T, Angerhaus D, Drewke E, Schneppenheim S, Schneppenheim R. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood. 2006 Mar 15;107(6):2339-45. doi: 10.1182/blood-2005-04-1758. Epub 2005 Dec 1. PMID: 16322474."	VWF	VCEP supp_VWD 2A2B2M functional assays	2A multimerization	5	No	strong and supporting	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	19422453	"Baronciani L, Federici AB, Punzo M, Solimando M, Cozzi G, La Marca S, Rubini V, Canciani MT, Mannucci PM. Type 2A (IIH) von Willebrand disease is due to mutations that affect von Willebrand factor multimerization. J Thromb Haemost. 2009 Jul;7(7):1114-22. doi: 10.1111/j.1538-7836.2009.03457.x. Epub 2009 Apr 24. PMID: 19422453."	VWF	VCEP supp_VWD 2A2B2M functional assays	2A multimerization	3	No	strong and supporting	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	22431572	"Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood. 2012 May 10;119(19):4543-53. doi: 10.1182/blood-2011-06-360875. Epub 2012 Mar 19. PMID: 22431572; PMCID: PMC3362367."	VWF	VCEP supp_VWD 2A2B2M functional assays	2A multimerization	13	No	strong and supporting	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	22905953	"Wang JW, Valentijn JA, Valentijn KM, Dragt BS, Voorberg J, Reitsma PH, Eikenboom J. Formation of platelet-binding von Willebrand factor strings on non-endothelial cells. J Thromb Haemost. 2012 Oct;10(10):2168-78. doi: 10.1111/j.1538-7836.2012.04891.x. PMID: 22905953."	VWF	VCEP supp_VWD 2A2B2M functional assays	2A multimerization	2	No	strong and supporting	none
ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF	23539537	"Yadegari H, Driesen J, Pavlova A, Biswas A, Ivaskevicius V, Klamroth R, Oldenburg J. Insights into pathological mechanisms of missense mutations in C-terminal domains of von Willebrand factor causing qualitative or quantitative von Willebrand disease. Haematologica. 2013 Aug;98(8):1315-23. doi: 10.3324/haematol.2013.084111. Epub 2013 Mar 28. PMID: 23539537; PMCID: PMC3729914."	VWF	VCEP supp_VWD 2A2B2M functional assays	2A multimerization	5	No	strong and supporting	none
